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N-Thiolated β-Lactams: Chemistry, SAR and Intracellular Target 
of a Novel Class of Antimicrobial and Anticancer Agents 
 
Bart Allan Heldreth 
 
ABSTRACT 
 
N-Thiolated β-lactams (1) represent a promising new group of compounds with 
potent inhibition effects on bacteria, like Bacillus anthracis and methicillin resistant 
Staphylococcus aureus, and onco-systems, like breast cancer and leukemia. Originally 
developed as part of a synthetic pathway to bicyclic lactams, N-thiolated β-lactams have 
been shown in this laboratory to possess intriguing biological activities. The antibacterial 
activities of this new class of agents rely on novel structural features unlike those of any 
existing family of β-lactam drugs. The lactams seem to exert their effects intracellularly, 
requiring passage of the bioactive species through the cellular membrane, rather than 
acting extracellularly on cell wall components in the manner of penicillin and related 
antibiotics. The lipophilic nature of these molecules, which lack the polar side chain 
functionality of all other microbially-active β-lactams, suggests the compounds do not 
target the penicillin binding proteins within bacterial membranes but instead pass through 
these membranes. The biological target of these compounds has been investigated. The 
most active members of this β-lactam class appear to be those bearing a small branched 
alkyl chain on the sulfur atom. The effects of stereochemistry, branching and chain length 
of the sulfur group on bioactivities were studied. This dissertation is divided into six 
chapters. A review of organosulfur anti-infectives is discussed in Chapter 1. The types of 
existing antibiotics and their modes of action will be discussed in Chapter 2. The 
synthesis of these novel agents is discussed in Chapter 3. A structure-activity relationship 
of these lactam analogues is discussed in Chapter 4. And Chapters 5 and 6 demonstrate a 
novel mode of action and biological target for these drugs using techniques which include 
target identification, metabolic effects, and reactivity kinetics. 
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CHAPTER ONE 
INVESTIGATIONS IN ORGANOSULFUR ANTI-INFECTIVES 
 
 
 An all too often overlooked group of anti-infective compounds are those whose 
biological activity is based on sulfur functionalities. As a prelude to my research on N-
thiolated β-lactams, this chapter provides a review of organosulfur anti-infectives. 
1.1.1 General Introduction 
As far back as 1000 B.C. elemental sulfur (S8) (1) was used, at the very least, as a 
pesticide.  In 1824 S8 was shown to treat peach mildew[1] and over the centuries, S8 has 
successfully been applied as a fungicide to protect a wide variety of plants against fungal 
infestation. The current rationale for these antifungal properties is that S8 is absorbed by 
the spores of the fungi, and converted within the fungi to toxic hydrogen sulfide, a 
compound which could have deleterious effects on mitochondrial respiration.[1] Although 
the mode of S8’s antifungal action is not fully defined, there is no doubt of its dependency 
on the reaction of sulfur with a biological target.     
S
S
S S
S
S
SS
 
 
1 
 
Figure (1.1). Elemental Sulfur S8 
The use of organosulfur compounds to control the onset or progression of 
infectious diseases in humans and animals also has its roots dating back to early times, 
when ancient Egyptians recognized the potent medicinal effects of naturally occurring 
 1
 organosulfur substances from leeks. In this report we summarize the types of molecules 
and reaction mechanisms associated with the anti-infective properties of various 
organosulfur substances. 
1.1.2 Classes of Biologically-Active Organosulfur Compounds 
Organic compounds that contain sulfur cover an extraordinary range of chemical 
structures and reactivities. Many of these have biological activity. In the simplest case, 
the presence of one or more sulfur atoms in a biologically active molecule may not 
actually give the compound its biological effects, but rather may act as a non-participant 
in a side chain residue or an innocuous constituency of the molecular framework. 
A few prime examples are the bicyclic beta-lactams, including penicillins (2), 
cephalosporins (3), and penems (4), and the sulfa drugs (5), whose anti-infective activity 
is not related to sulfur-centered events (Figure 1.2).  
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Figure (1.2). Bicyclic β-Lactams and Sulfa Drugs. 
Alternatively, the presence of a sulfur atom in a bioactive molecule may exert a 
more definitive, yet subtle, effect on its biological activity, such as the case of the 
 2
 thiosugars (6a-c) and thionucleosides (7). These sulfur analogues of the natural sugars 
and nucleosides act as inhibitors of glycosidases and reverse transcriptases, 
respectively.[2-8] It has been documented that these properties are due to the 
conformational and stereoelectronic changes brought about by the replacement of oxygen 
with sulfur in the heterocyclic ring. However, even in these molecules, the sulfur atom 
does not, per se, play a central role in the reaction of the molecule with a biological 
entity.  
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D-5-Thioglucose L-5-Thiofucose D-5-Thiomannose
 
Figure (1.3). Thiosugars and Thionucleosides. 
In many other cases, however, the bioactivity of an organosulfur compound may 
be directly attributable to the reactivity of the sulfur center, which is certainly the case for 
the sulfur mustards (8). Here, the sulfur atom is responsible for activating the compound 
toward nucleophilic attack by displacing a chlorine atom. Once activated, the sulfur atom 
is then a potent electrophile for attack by a biological nucleophile (Figure 1.4).  
 
 3
 Cl
S
Cl
Cl
S
Cl
S
Nu
Nu
8
 
Figure (1.4). Sulfur Mustard. 
In many instances, it is the sulfur center itself which is the site of chemical 
attachment of the biomolecules to its target. What follows in this review is a discussion of 
the antibacterial, antifungal, antiviral, and antiparasitic activities of organosulfur 
compounds whose mode of action depends on the reactivity of one or more sulfur atoms 
in that molecule with a biological target.  
1.1.3 Relationship Between Reactivity of Organosulfur Compounds and 
Microbiological Activity. 
Biologically active organosulfur compounds can interfere with the processes 
associated with human infections and disease through a number of common pathways, 
depending on the type of sulfur functionality that is present and the nature of its 
reactivity. For instance, thiols are relatively reactive groups which can act as either 
powerful nucleophiles or reducing agents, depending on the nature of the electrophile 
(E+), the thiol substituent (R),  and the local environment in which the reaction occurs 
(equations 1 and 2).  
 4
 E
R-S-E  +   H                          (1)
R-SH+
R-S     +    E   +    H              (2)  
Figure (1.5). Reactions of Thiol Compounds with Electrophiles.  
Disulfides, on the other hand, behave as electrophilic reactants in the presence of 
various thiophilic nucleophiles, resulting in the heterolytic cleavage of the sulfur-sulfur 
bond (equation 3). Intracellular nucleophiles such as glutathione (9) and thioredoxins 
(trx’s), for example, can react rapidly with di- and trisulfide compounds to disrupt 
cellular stasis (Figure 1.6).[9,10]  
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Figure (1.6). Oxidation Reactions of Disulfides. 
Alternatively, disulfides can act as electrophilic oxidants (equation 4), which can 
lead to the generation of superoxide and hydrogen peroxide within the cell via redox 
pathways, thereby affecting oxidative conditions in and around the cell (Figure 1.8). 
These two pathways, represented by equations 3 and 4, are generally competing within 
the cell, and may both lead to cell death.  
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 A number of other sulfur functionalities act in similar fashion to either thiols or 
disulfides and thus serve as masked versions of these reactive groups. Bismuth thiols 
(Figure 1.21), for instance,  have greater potency, increased selectivity, reduced toxicity, 
and better stability than the free thiol, while trisulfides, such as that found in calichemicin 
(10), and certain sulfenamides, behave mechanistically similarly to disulfides. Some 
trisulfide compounds may also result in the generation of a destructive radical species, 
such as the case of calichemicin (10) and esperamicins (11).[11-16]
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Figure (1.7). Calichemicin, an Enediyne Trisulfide. 
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Figure (1.8). Reactions of Disulfide Compounds with Nucleophiles. 
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Figure (1.9). Namenamicin, a Novel Enediyne. 
The focus of this review centers on the structures and modes of action of those 
agents whose anti-infective properties have been proven, or postulated, to be dependent 
on the sulfur atom as the primary site of biochemical reactivity. This list includes those 
already mentioned, thiols, disulfides, trisulfides, as well as related moieties such as 
sulfenamides, thiosulfinates and thiosulfonates.  Compounds that contain groups such as 
sulfenic acids, sulfoxides and more highly oxidized compounds like sulfinic acids, 
sulfones, sulfonic acids, sulfamates and sulfate esters are not discussed here since their 
activities are rarely directly dependent on the sulfur atoms. Those compounds that are 
only dependent on sulfur for such properties as architecture, polarity, stability or 
solubility are also not included here.  
1.2.1 The Key Biological Targets of Organosulfur Drugs 
 Over the course of time, living cells have developed defenses against the harmful 
effect of biological oxidants, or disinfectants. The thiol-disulfide redox equilibrium in 
cells is central to this natural defense mechanism, and thus serves as a potentially 
valuable target of sulfur-based antibiotics. Nature protects microbes from oxidative stress 
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by maintaining high thiol:disulfide ratios, typically 19:1 or higher. Disruption of this 
redox system can alter many vital cellular activities such as regulation of protein activity, 
regeneration of enzymatic cofactors and reductases, like ribonucleotide reductase, and a 
host of other processes where an antioxidant is required.[17]  
1.2.2 Glutathione-based Systems 
One of the most important thiol/disulfide dyads found in many cell types is 
glutathione (9) (γ-L-glutamyl-L-cysteinylglycine), a tripeptide assembled exclusively in 
the cell. Glutathione is produced biologically via the glutaredoxin enzymatic pathway in 
two steps: 1) formation of the glutamyl-cysteine adduct and 2) subsequent attachment 
addition of glycine to the c-terminus. The equilibrium between free thiol and disulfide, at 
stasis, is typically maintained at a cytoplasmic thiol concentration of around 90%. 
Although intracellular glutathione concentrations are notoriously difficult to measure, and 
can vary throughout the life cycle of a cell, cell lines with high intracellular glutathione 
levels are generally less susceptible to damage by organosulfur drugs.[18] Serving a 
primary role as an antioxidant, glutathione is extremely effective in scavenging reactive 
free radicals, electrophiles and other destructive oxidants in the cytoplasm. Glutathione 
can react directly with various drugs to deactivate them before they are able to inflict 
irreversible damage, while also serving to reactivate enzymes that have been inhibited as 
mixed disulfides formed between a drug and enzyme. In response to this protective 
mechanism afforded by glutathione, nature has cleverly designed prodrug molecules such 
as the enediyne trisulfides and anthracyclines which can interact directly with glutathione 
as a way to be biochemically activated within the target cell. Inhibition of glutathione’s 
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antioxidant abilities can be induced by formation of glutathione-S-S-drug mixed 
disulfides. The rate of thiol cleavage of the sulfur-sulfur bond of the glutathione disulfide 
is directly proportional to twice the protic acidity of the free thiol.[19]  
1.2.3 Coenzyme A-based Systems 
In the past it was commonplace to assume the presence of glutathione in all 
organisms. Glutathione, however, is not entirely ubiquitous. Some bacteria are totally 
devoid of glutathione, but in its place have some other thiol/disulfide-based redox system. 
S. aureus, for example, does not generate or utilize glutathione at all, but rather produces 
millimolar levels of the nucleosidic entity, coenzyme A (12) (CoA).[20]
  At stasis, the bacterium maintains a ratio of thiol:disulfide of about 95:5, via 
coenzyme A disulfide reductase (CoADR) (Figure 1.10). This is extraordinarily specific 
in its ability to reduce CoA disulfide. Mixed disulfides formed between CoA and 
glutathione, or other thiophilic agents, are typically unable to be reduced by 
CoADR.[20,21] Therefore, anti-infective compounds that can form CoADR resistant mixed 
disulfides with CoA can offer an effective mode of inhibition against S. aureus. Indeed, 
glutathione is an inhibitor of the redox cycle of CoA and is detrimental to the growth of 
this bacterium. 
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Figure (1.10). Coenzyme A Redox System. 
1.2.4 Thioredoxin-based Systems 
Another very important group of native cellular thiols / disulfides are the 
thioredoxins (trx’s) and a related subfamily, the disulfide bridge forming enzymes 
(Dsb’s), which span through the bacterial membrane connecting the cytoplasm with the 
periplasm. The characteristic Cys-X-X-Cys motif in the structures of the trx’s is highly 
conserved in many bacteria. These dithiols undergo reversible oxidation and can quickly 
react with non-native thiols or disulfides. Before a drug even passes through the 
membrane of a bacterium however, a subfamily of thioredoxins, the Dsb’s, could 
potentially intervene. Formation of mixed disulfides between the trx’s and the organothio 
compound can thereby inhibit enzymatic reduction and thus can shut down cellular 
function. Figure 11 illustrates the cellular function of trx’s and Dsb’s. 
Dsb’s, for the most part, inhabit the cytoplasmic membrane with exposed (Cys-X-
X-Cys) functionalities on both the cytoplasmic and periplasmic surfaces. Dsb’s are 
involved in electron transport across the membrane and serve as a signaling mechanism, 
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communicating the oxidation state of the cytoplasmic trx’s with the oxidation state on the 
periplasmic side. Disulfide formation involving trx motifs on either side of the membrane 
can cause disruption of the Dsb’s electron transport abilities, affecting a host of cellular 
processes such as respiration and cytochrome syntheses. Although there is evidence that 
Dsb repair enzymes exist[9,10], their effectiveness and versatility against non-native thiols 
or sulfides has not been charted. So, these extraordinarily reactive, native groups 
represent significant potential as drug targets. Especially of interest is that human 
thioredoxin has a greater distance between cysteine residues, Cys-X-X-X-X-Cys, which 
could allow for development of inactivators which are specific for the bacterial 
thioredoxins.[22]
 
  
Figure (1.11). Potential Drug Interactions with Thioredoxins.  
(a) Normal function of disulfide bridge forming enzymes (Dsb’s), allowing electron flow between Dsb’s 
and thioredoxins (trx’s). (b) Drug molecules with thiol or disulfide functionalities can bind irreversibly with 
the Dsb, on either the cytoplasmic or periplasmic side, and thereby inhibit communication across the 
bacterial membrane. (c)As well, direct, irreversible, binding of an organosulfur molecule to free 
thioredoxins (trx) can also shut down these important redox mechanisms.  
 
1.2.5 Mycothiol-based Systems 
Actinomycetes also do not produce glutathione, but generate mycothiol (13) 
instead as their primary antioxidant.[23] First discovered in a species of Streptomyces, and 
then identified in Mycobacterium bovis, mycothiol has since been found to be prevalent 
only amongst actinomycetes and is produced in high levels by mycobacteria. 
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 Consequently, these cellular antioxidants have great potential as targets for anti-
tuberculosis agents. 
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Figure (1.12). Mycothiol (13). 
 
1.2.6 Other Cellular Targets 
Another potential intracellular thiol target is adenosine triphosphate synthase 
(ATPase). ATPase is the enzyme responsible for regeneration of the all-important energy 
source of cells, adenosine triphosphate (ATP) (14).  ATPase, which sits on the 
mitochondria, contains a reactive, free thiol which is paramount to activity. Inhibition of 
ATPase, therefore, can be achieved by formation of a mixed disulfide.  
One final target of note is the phosphoenol pyruvate phosphotransferase system 
which is involved in the sugar uptake of some bacteria. This system employs an enzyme 
whose structure is moderately conserved between species, carries a molecular weight of 
approximately 70,000, and is extremely vulnerable to attack by free thiols.[24]  
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Figure (1.13). ATP 
 
1.3.0 Antibacterial Organosulfur Compounds 
1.3.1 Introduction  
Bacterial cells differ greatly from human and animal cells, thus providing a 
number of targets that are specific to bacterial infection, but not healthy tissues. A major 
focus to antibacterial development has been on finding compounds that can interrupt 
bacterial cell wall biosynthesis without inducing harm to human cells. In the case of 
Gram-negative bacteria there is also an additional cell membrane on the exterior of the 
cell wall which can block the entry of some polar antibacterial agents. The remaining 
classical targets of antibiotics are tetrahydrofolate, DNA, RNA and protein synthesis. 
However, the search is on for novel bacterial targets that can damage bacteria through 
non-classical pathways. 
For thousands of years homeopathic medicine extracts, and oils from leeks such 
as garlic, onions, shallots, chives and scallions, have been successfully used to treat 
bacterial infections.[25] Early experimentation found that thoroughly dried formulations 
were totally ineffective, thus pointing to volatile reagents as the active anti-infective 
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agents. We now know that the responsible compounds in these remedies are low 
molecular weight organosulfur compounds.[24,25]
Today, extracts are still used abundantly. In China, Dasuansu (diallyl trisulfide) is 
a popular commercial product for the treatment of bacterial, fungal and parasitic 
infections. Garlic-based remedies spawned the initial interest of medicinal sulfur 
chemistry and continue to be actively investigated.[26]
In 1944 a rather smelly extract was determined to be a primary agent responsible 
for garlic’s wide range of antibacterial properties.[21] Three years later the first structural 
proof of a sulfur containing garlic extract was determined, by chemical synthesis, to be a 
thiosulfinate. This component was named Allicin (15) (originating from Alluim sativum, 
the Latin name for garlic).   
Allicin has been shown to have potent in vitro antibiotic activity against 
Escherichia coli, Staphylococcus aureus, Streptococcus pyrogenes, Proteus mirabilis, 
Pseudomonas aeruginosa, Acinetobacter baumanii, and Klebsiella pneumonie (Table 
1.1).[27,28] The likely mode of action of Allicin involves reaction of the thiosulfinate with 
a cellular thiol to produce a mixed disulfide.[29] The identity of the native thiol has not 
been definitively proven, but is likely to be a thioredoxin or glutaredoxin. 
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Figure (1.14). Potential Mode of Action of Allicin. 
 
Table 1.1. Antibacterial Activities of Allicin(15).[28]
 
Bacterial Strain 
LD50 
(µg/ml)
Escherichia coli 15 
E. coli (multidrug resistant) 15 
Staphylococcus aureus 12 
S. aureus (methicillin resistant) 12 
Streptococcus pyogenes 3 
Streptococcus β hemolyticus >100 
Proteus mirabilis 15 
P. mirabilis (multidrug resistant) >30 
Pseudomonas aeruginosa 15 
P. aeruginosa (multidrug resistant) >100 
Acinetobacter baumanii 15 
Klebsiella pneumoniae 8 
Enterococcus faecium >100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although Allicin was the first sulfur-containing extract identified from garlic, it is 
certainly not the only one: other isolates with in vitro antibacterial activities include 
diallyl disulfide (16), diallyl trisulfide (17), Ajoene (18), diallyl sulfide (19), S-
allylmercaptocysteine (20), and S-allyl-L-cysteine (21).[25,27-31]
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Figure (1.15). Natural Antibiotics from Garlic. 
Many of these substances have also been tested for in vivo activities, including the 
diallyl sulfide and diallyl disulfide, which have potent activity against murine methicillin-
resistant Staphylococcus aureus (MRSA) infections.[32] The mechanism by which they 
exert their bacteriostatic effects has not been fully defined but undoubtedly relies on the 
sulfur functionalities.  
1.3.2 Thiols 
 Thiol-bearing enzymes, such as glutaredoxin and thioredoxin, often lose some or 
all of their activity in the presence of non-native (to the cell) thiols like allyl mercaptan. 
To that effect, thiol-bearing therapeutics are often effective at shutting down enzymatic 
pathways regulated by these proteins. Although there are a large number of small, natural 
product thiols now known to possess antibiotic activities, there are only a few 
synthetically-derived thiols that have been shown to have antibacterial properties. A trio 
of thiodiazole aromatics, 22a-c, are reported to have minimum inhibitory concentrations 
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 (MICs) against Staphylococcus aureus in the 31-62 µg/ml range, but impose no effect on 
E. coli.[33] The reasons for this are not known. 
Compounds 23a-c, synthetic precursors to 22a-c, possess much lower antibiotic 
activities, with MIC’s above 125 µg/ml for Staphylococcus aureus. 
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Figure (1.16). S. aureus-Active Thiodiazoles. 
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Figure (1.17). Mercaptotriazoles, Precursors to the Thiodiazoles. 
Some mercaptopyrimidines have also been shown to have antibiotic activities.[34] 
Biological evaluation of 5-mercapto-2’-deoxyuridine (24b) in comparison to a known 
antibiotic, 5-fluoro analogue (24a), has been reported. Although weaker than the 5-fluoro 
analogue, the mercapto analogue shows selectivity to Lactobacillus leichmannii over 
Lactobacillus arabinosus and Streptococcus faecalis, which is not observed for the fluoro 
analogue (Table 1.2). As well, there is a synergistic effect when 5-mercapto-2’-
deoxyuridine is used in tandem with the fluoro analogue, indicating that the two 
compounds exert different modes of action in their inhibition of Lactobacillus 
leichmannii. The potency of the drug is displayed by an IC50 of 0.06 µM. Interestingly, 
for the 5-mercaptouracil, this selectivity seems to be reversed, with L. faecalis being the 
most greatly affected. Similar properties are seen with uracil analogues 25. 
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Figure (1.18). 5-Fluoro-2’-deoxyuridine (24a) and 5-Thio Analogue (24b). 
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Figure (1.19). 5-Fluorouracil (25a) and 5-Thio Analogue (25b). 
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Figure (1.20). Example of a Boron-Complexed Benzothiazoline Antibacterial. 
Nisin Z is an antimicrobial peptide (lantibiotic), comprised of 34 amino acids with 
5 free thiols, that effectively inhibits growth of various gram-positive bacteria.[36] It exerts 
its antimicrobial activity by permeabilizing the cytoplasmic membrane of target bacteria. 
This leads to the release of small cytoplasmic compounds, depolarization of the 
membrane potential, and ultimately cell death. The free thiols along the backbone of this 
peptide are required for the antibiotic properties, since blockage or removal of these 
thiols completely destroys activity. The reasons for this are not yet fully understood. 
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Table 1.2. IC50 Values (µM) of Fluoro- and Mercapto-Substituted Pyrimidines 
(24a,b and 25a,b).[34]
Compound L.leichmannii L. arabinosus L. faecalis
5-fluorodeoxyuridine (24a) 0.03 0.001 0.00001 
5-mercaptodeoxyuridine (24b) 0.06 4 0.1 
5-fluorouracil (25a) 0.04 0.2 0.00005 
5-mercaptouracil (25b) 30 700 3 
 
As mentioned, certain groups of enzymes within bacteria cells require free thiols 
for their activity, which can in some cases be inhibited by non-native thiols. These 
proteins are especially susceptible to inactivation by metal thiol complexes, such as 
boron-complexed benzothiazolines (26), which form mixed disulfides with thiol-
containing proteins to block the metabolic pathway.[35] Compounds 26 have shown 
promising in vitro activities against Escherichia coli, Staphylococcus aureus, Klebsiella 
aerogenous and Pseudomonas cepacicola. The levels of biocidal activity such complexes 
have against different microorganisms depend primarily on the permeability of the cells. 
Bearing the idea that free thiols can be responsible for biological activity, it is 
important to realize the potential for these reagents to dimerize and thus lower, or even 
abolish, their in vivo activity. Metal-thiol coordinations can prevent these dimerizations 
without destroying activity of the thiol. 
To prove this, one report compared the antibacterial effects of the sodium thiolate, 
free thiol, and tin thiolate of 5,7-dichloroquinone (27a-c).[37,38] Presumably, disulfide 
formation would be more likely for the sodium thiolate than free thiol, and more for the 
free thiol than for the tin thiolate. The three compounds were evaluated against four 
bacteria: Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus and Bacillus 
 cereus (Table 1.3). The sodium thiolate displayed no antibacterial activity, while the free 
thiol showed MICs in the 100 to 200 µg/ml range and the tin thiolate had MICs in the 
37.5 to 50 µg/ml range. This suggests that spontaneous dimerization of thiol 
antibacterials may be a limiting effect which can be overcome by metal coordination. 
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Figure (1.21). 5,7-Dichloroquinoline Thiol and Metallated Derivatives. 
It seems that the tin entity is not responsible for this activity, but merely preserves the 
thiolate from disulfide formation. This has been demonstrated conclusively in the use of 
tin thiol derivatives for antifungal treatment (vide infra). 
 
Table 1.3. MIC’s of Quinoline Derivatives 27a-c. 
 
Compound S.aureus E.coli
27a >128 >128 
27b 103 102.5 
27c 50 37.5 
 
 
 
 
 
Similarly, some simple bismuth-coordinated thiols (BTs) have been reported to 
possess potent antibacterial properties.[39] Bismuth-2,3-mercaptopropanol (BisBAL) (28), 
bismuth-3,4-dimercaptotoluene (BisTOL) (29), bismuth-1,2-ethanedithiol (BisEDT) (30), 
and bismuth-pyrithione (BisPYR) (31) have been shown to effectively inhibit the growth 
of MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE), with MIC’s in 
the single digits and low MBC’s (Table 1.4).  
 21
 OH
SH
SH
Bi
CH3
SH
SH Bi
HO SH
SH
Bi N SH
OH Bi
31
28 29
30  
Figure (1.22). Bismuth-Coordinated Thiols. 
Table 1.4. Bioactivities of Bismuth-Coordinated Thiols Against Methicillin-resistant 
S. aureus. 
Compound MIC MBC 
BisBAL (28) 8.3 18 
BisTOL (29) 4.4 9 
BisEDT (30) 2.4 73  
BisPyr (31) 6.7 14 
 
 
 
 
 
 
 
As well, these bismuth thiols prevent growth of bacterial biofilms on coated 
indwelling medical devices, such as catheters and intravascular lines. Synthesis of BTs is 
straightforward, simply requiring the addition of bismuth nitrate to the appropriate 
thiol.[40]
1.3.3 Disulfides 
 As therapeutic agents, disulfides usually serve one of two purposes: 1) as inactive 
structural components of biomolecules, or 2) as biological oxidants. In the latter role, 
disulfides are particularly prone to react with thiols to give biologically-inert mixed 
disulfide adducts.  
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Many of the leek extracts, like Ajoene (18), create the same type of mixed 
disulfide products with native thiols that are seen with the corresponding thiol drugs.[31] 
This leads to effective antibacterial activities such as those shown in Table 1.5. 
 
Table 1.5. Antibacterial Activities of Ajoene (18). 
Bacterial Strain MIC (µg/ml) 
Bacillus cereus 4 
Bacillus subtilis 4 
Staphylococcus aureus 16 
Mycobacterium smegmatis 4 
Mycobacterium pheli 14 
Micrococcus luteus 136 
Lactobacillus plantarum 19 
Streptococcus spp. 56 
Streptomyces griseus 4 
Escherichia coli 116 
Klebsiella pneumoniae 152 
Pseudomonas aeruginosa >500 
Xanthomonas maltophilia 118 
 
 Epipoly-thiodioxopiperazines (ETP’s) are a class of fungal metabolites of 
Candida, Thermoascus and Penicillium, to name a few, that possess characteristic 
bridged disulfide piperazinedione six-membered rings. These antibiotics only inhibit 
Gram-negative bacteria, which is likely related to their outer membrane permeability, and 
are prone to nucleophilic attack on their electrophilic disulfide bridge. Gliotoxin (32) and 
related ETP’s are reported to act as oxidants by at least two different pathways: 1) 
generation of superoxide and hydrogen peroxide via glutathione redox cycling, and 2) 
sulfenylation of native thiols of certain proteins to make catalytically defunct mixed 
 disulfides.[41,42] Which sulfur center in gliotoxin is the site of enzymatic attack is still 
unclear but it is likely that both may be involved. 
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Figure (1.23). Gliotoxin, an Epipolythiodioxopiperazine (ETP) Antibacterial. 
Although somewhat rare in nature, some cyclic polysulfides (33-35) occur in a 
few fungi and aquatic organic organisms.[43,44] The intermittent carbon linkages in these 
molecules distinguish these analogues from S8 and enhance solubility in non-aqueous 
environments.
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Figure (1.24). Cyclic Polysulfide Natural Products. 
These cyclic systems contain reactive disulfide bridges that most likely behave 
like those of other disulfide antibiotics. These compounds have been found to inhibit 
Staphylococcus aureus, Streptococcus faecium, Escherichia coli, Klebsiella sp., Proteus 
mirabilis and Pseudomonas aeruginosa.  
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 Similarly, the natural product Leinamycin (36) has potent inhibition activity, MIC 
= 0.03 µg/ml, against Bacillus subtilus.[45] Leinamycin has an intriguing mechanism of 
action. It is believed that Leinamycin reacts with cellular thiols to form, in a few 
additional intramolecular steps, an episulfenium cation which can, in turn, alkylate 
DNA.[46-48] As a DNA alkylater, Leinamycin blocks cellular replication in bacteria. 
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Figure (1.25) Leinamycin’s Mode of Action 
Isolated from both a species of Psammaplysilla and Thorectopsamma xana, a trio 
of closely related disulfides were discovered with noteworthy antibacterial activity.[49] 
Psammaplin A (37) and the dimer, Bisaprasin (38), along with Psammaplin D (39) all 
demonstrated growth inhibition of Staphylococcus aureus and Bacillus subtilis. 
Psammaplin D, interestingly, also shows activity against the Gram-negative bacterium 
Trichophyton mentagraphytes.[50]
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 Isolated from a tunicate, Polycitorella mariae, a novel disulfide termed 
Citorellamine (40) has been reported to have significant antimicrobial activity.[51] 
Originally assigned the structure of a sulfide, the disulfide Citorellamine demonstrates 
potent antibacterial activity against Staphylococcus aureus, Bacillus subtilis and 
Escherichia coli as well as cytotoxicity in some cancer cell lines.[52]  
Disulfides with interesting antibacterial activities also occur in proteins 
specifically synthesized by life forms for defense. These antibiotics are found most 
commonly in marine sources, and usually contain two neighboring cysteine residues. One 
such antibacterial protein, from a marine decapod, displayed potent inhibition of 
Planococcus citreus, Planococcus kocurii, Aerococcus viridans, and Micrococcus luteus 
and an extraordinarily strong resistance to heat damage.[53]  
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Figure (1.26). Psammaplin A (37). 
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Figure (27). Bisaprasin (38) 
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Figure (1.28). Psammaplin D (39). 
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Figure (1.29). Citorellamine (40). 
 
1.3.4 Trisulfides 
 Trisulfides found in garlic, such as diallyl trisulfide and allyl methyl trisulfide, 
can act as antibacterial agents in the same way as disulfides, but with greater efficacy. 
The antibacterial activity of some cyclic polysulfides can be attributed to a trisulfide 
bridge, as much as previous examples owe their activity to a disulfide bridge.[43,44] 4-
Dioxo-1,2,4,6-tetrathiepane (41), an extract from the red alga Chondria californica, has 
potent antibacterial activity against Vibrio anguillarium, the causative agent of a tropical 
fish disease. 
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Figure (1.30). 4-Dioxo-1,2,4,6-tetrathiepane. 
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Enantiomeric marine natural products are fairly uncommon, especially those with 
two chiral centers. However, a pair of Enantiomeric trisulfide alkaloids (42) from the 
New Zealand ascidian Hypsistozoa fasmeriana have been identified and shown to possess 
weak (4 mm zone of inhibition by a 120 µg/disk), but identical, activities against Bacillus 
subtilis and weak (10% inhibition at 12.5µg/ml) activities against Mycobacterium 
tuberculosis.[54] Similar Ascidian natural products without the trisulfide functionality 
(43), but with a 1,3-dithiane instead, are completely devoid of antimicrobial activity. 
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Figure (1.31). Ascidian Trisulfide and Dithiane.  
Also part of the trisulfide family of antibiotics are the enediyne trisulfide 
antitumor antibiotics, Calichemicin (10), natural product of Micromonospora 
echinospora, and Namenamicin (11), Esperamicins natural product of Actinmadura 
verrucosospora, Although these antibiotics are not currently used to treat infection, in 
anticancer systems these compounds have been shown to undergo an intricate cascade of 
intramolecular reactions initiated by glutathione attack, resulting in an intensely reactive 
radical species. In the first step of this process, reaction of the trisulfide group with 
glutathione generates a free thiolate anion which in turn undergoes a Michael addition 
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 across the α,β-saturated ketone. This subtle change in hybridization of the carbons allows 
the enediyne to undergo Bergman cycloaromatization, producing the phenylene 
diradical.[13] These diradicals are believed to cleave DNA by sequentially stripping off 
hydrogen atoms along the minor grove of the double helix. Even though their mechanism 
of antibacterial action has not been proven to be the same as that of the anticancer 
mechanism (Figure 36), it is likely that the trisulfide moiety is involved as an 
electrophilic reactant with cellular thiols (Table 1.6). 
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Figure (1.32). Proposed Mechanism of Enediyne Bioactivation. 
 
Table 1.6. Antibacterial Activity of Representative Enediynes, 10 and 11, versus 
Penicillin G.[11,12]
 
 
 
 
   MIC(µg/ml)   
Bacteria Calicheamicin Namenamicin Penicillin G
Bacillus subtilis 0.00005 0.03 0.25 
Staphylococcus aureus 0.000001 0.001 0.015 
Enterococcus faecium 0.00012 0.03 128 
Escherichia coli 0.12 0.12 32 
Klebsiella pneumoniae 0.25 0.06 128 
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 1.3.5 Pentasulfides 
 Within the Didemnidae or tunicate family, Lissoclinumi species are rich sources 
of organosulfur antibiotics. One such isolate Lissoclinotoxin A (44), demonstrated potent 
growth inhibition of a number of bacteria, including S. aureus, Streptococcus faecalis, 
Cirrobacter species, Klebsiella species, E. coli, Enterobacter species, Serratia species, 
Salmonella species, Pseudomonas aeruginosa, Acinetobacter, and Proteus species (Table 
1.7).[55]
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Figure (1.33). Lissoclinotoxin A 
 
Table 1.7. Antibacterial Activities of Lissoclinotoxin A (44). 
 
Bacteria
MIC
44
(µg/ml) 
Cefotaxim
S. aureus 0.08 - 0.15 1.2 - 10 
S. faecalis 0.3 - 0.6 0.6 - 2.5 
Cirrobacter spp. 0.3 - 0.6 0.08 - 10 
Klesiella spp. 0.3 - 0.6 0.01 - 0.15
E. coli 0.15 - 0.6 0.005 - 5 
Enterobacter spp. 0.3 - 0.6 0.08 - 40 
Serratia spp. 0.3 - 0.6 0.08 - 2.5 
Salmonella spp. 0.3 - 0.6 0.08 - 3 
P. aeruginosa 2.5 - 10 2.5 - 40 
Acinetobacter 0.3 10 
Proteus spp. 0.15 - 0.6 0.005 - 0.3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30
 1.3.6 N-Thiolated Compounds 
N-Sulfenylated monocyclic β-lactams (45) are another class of sulfur-containing 
antibacterial compounds recently discovered to have an unusual mode of action, where 
the N-S functionality may interact with cellular thiols in the same fashion as a 
disulfide.[56]  
Despite the presence of a β-lactam ring, the mode of action of these N-thiolated 
compounds is totally different to that of the penicillins and other beta-lactam drugs which 
act as cell wall biosynthesis inhibitors. It is believed that an intracellular thiol attacks the 
sulfur atom to form a mixed disulfide which in turn causes inhibition of bacterial growth. 
These thiolated lactams show a narrow range of antibacterial properties, including 
Staphylococcus strains such as MRSA and S. epidermidis. Full details on the synthesis 
and biological activities is covered in the following chapters. 
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Figure (1.34). N-Sulfenylated-β-Lactam 
Another sulfenamide, 1,2-benzoisothiazolin-3-one (BIT) (46), has shown weak 
activity against Staphylococcus aureus, with an MIC around 100 µg/ml.[57]  
S
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Figure (1.35). BIT 
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 BIT has been shown to inhibit the action of a number of intracellular thiols such as 
glutathione and ATPase. The mode of action has been linked to an inhibitory effect on 
cellular respiration upon metabolic uptake. 
Lansoprazole (47), a drug originally designed as a gastric acid pump inhibitor, has 
been shown to rearrange in the acidic environment of the stomach to a sulfenamide (48), 
which is an inhibitor of Helicobacter pylori.[58,59] H. pylori is considered to be a main 
culprit in the cause of gastric ulcers and therefore lansoprazole serves double duty as an 
antibiotic and an acid production reducer. Even though an intermediate sulfenic acid 
derivative of lansoprazole also displays anti-pylori activity, the sulfenamide affords fast 
action with an MIC value of 10 µg/ml. 
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Figure (1.36). Lansoprazole and in vivo Sulfenamide. 
 
1.4.0 Antifungal Organosulfur Compounds 
1.4.1 Introduction 
 In addition to their antibacterial properties many organosulfur compounds have 
fungistatic or fungicidal activity. Being eukaryotes, fungi comprise a separate group of 
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 microorganisms, having a membrane bound nucleus, a more extensive endoplasmic 
reticulum and mitochondria. Compared to bacteria, fungi have a very different cell wall 
which is built from a complex set of constituents including chitin (aminoglucans), 
polyuronids, galactosamine, melanin and various lipids. Fungal DNA is found isolated 
within the nucleus instead of dispersed throughout the cytoplasm, as in bacteria. Fungal 
infections are usually isolated to the dermis or mucosal membranes (superficial mycosis). 
However, with the increasing prevalence of immune deficiency diseases, like HIV-AIDS, 
development of treatments for internal and systemic fungal infections (deep mycosis) are 
now of significant concern.  
Although antifungal activity attributed to garlic extracts dates back to 1936, the 
first garlic isolate to display antifungal activity, Ajoene (Fig. (18)) against Aspergillus, 
was not reported until 1987.[60] Since then a number of other antifungal activities have 
been found for Ajoene, such as Candida and Paracoccidiodes (Table 1.8).[31]  
 
Table 1.8. Antifungal Activities of Ajoene (18). 
 
 Fungal Strain MIC (µg/ml)
Candida albicans 13 
Hanseniaspora valbyensis 11 
Pichia anomala 11 
Schizosaccharomyces 
pombe 5.5 
Saccharomyces cerevisiae 12 
 
 
 
 
 
 
 
 
 
Other garlic-derived natural products that exhibit potent antifungal activities 
include diallyl trisulfide (against Cryptococcal meningitis) and Allicin (against species of 
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 Candida, Cryptococcus, Trichophyton, Epidermophyton, and Microsporum, with MICs 
as low as 1.57 µg/ml)(Table 1.9).[28,32] The mode of action of these antifungal agents has 
yet to be fully elucidated, however, they are believed to function as sulfenylating agents, 
as they do in bacteria. 
 
Table 1.9. Antifungal Activities of Allicin (15). 
 
Fungal Strain MIC(µg/ml)
Candida albicans 0.3
C.albicans (clinical isolate) 0.8
C. neoformans 0.3
C. parapsilosis 0.15
C. tropicalis 0.3
C. krusei 0.3
Torulopsis glabrata 0.3
T.glabrata (clinical isolate) 1.9
 
 
 
 
 
 
 
 
 
 
1.4.2 Thiols 
 Due to the proliferation of thiol-bearing enzymes in a large majority of life forms, 
it is to be expected that anti-infective thiol compounds could be found in nature that can 
successfully inhibit the growth of fungi by formation of mixed disulfides. Consequently, 
some of the thiols examined earlier in this report for antibacterial activity are also 
effective antifungal reagents. 
 Closely related derivatives (49a-c) of the antibacterial mercaptotriazoles inhibit 
Candida albicans and Saccharomyces cerevisiae, with MIC values in the range of 12.5 to 
61 µg/ml.[34] Both the thiol and amine groups are believed to be required for antifungal 
activity, since the thiodiazole aromatics 22a-c (which lack the amino moiety) and their 
precursors 23a-c have no antifungal properties.  
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Figure (1.37). Mercaptotriazole Antifungals (49). 
The unsymmetrical boron-complexed benzothiazolines, BisBAL, BisTOL, 
BisEDT, BisPYR and BisβME, whose antibacterial properties were previously discussed 
(Table 1.4), all display weak antifungal activities, with MICs just above 200 µg/ml 
against Macrophomina phaseolina, Fusarium oxysporum and Aspergillus niger.[31] 
Comparatively, the marketed non-sulfur-containing drug, Bavistin, exhibits MIC values 
of approximately 100 µg/ml each. 
 Likewise, 5,7-dichloroquinoline-8-thiol and its sodium and tin thiolates (Figure 
1.21) have been examined against fungi.[28] As in the case of the antibacterials, the 
stannous thiolate showed the best antifungal activities, with MICs against Candida 
albicans and Saccharomyces cerevisiae of 50 µg/ml, while the free thiol and sodium 
thiolate displayed MICs of 128 and greater, respectively. To substantiate the claim that 
this is an antifungal effect of the thiol and not strictly a function of tin toxicity, another 
lab compared a relatively inactive control group of tin-2-thionaphthalenes to their free 
thiols and discovered almost equal antifungal activities. As well, the tin-thiolated 
compound was shown to be no more toxic (lethal dose = LD50 >100 µg/ml) than the free 
thiol itself.[29]
1.4.3 Sulfides 
 Although the mechanism of action of the Ajoene organosulfide, 18, is still under 
active investigation, it is likely that antifungal activity is the result of induced cell wall 
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 damage, since morphological changes in fungal cells treated with these compounds have 
been observed via scanning and transmission electron microscopy.[54]  
Six newly reported sulfide-bearing 1,4-naphthoquinones (50-55) have been found 
to display good to potent activities against Candida albicans, Cryptococcus neoformans, 
Sporothrix schenckii, Trichophyton mentagraphytes, Aspergillus fumigatus and 
Microsporum cannis, with MICs ranging from less than 0.78 to 50 µg/ml, a marked 
improvement over their respective oxygen counterparts[60]. As of yet, the mechanism of 
their activity is not understood, but may in fact be related to the oxidative potential of the 
naphthoquinone ring system. 
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Figure (1.38) Naphthoquinone Sulfides Antifungal Compounds. 
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 1.4.4 Disulfides 
 Disulfides are commonly found as toxins produced by fungi[43], however, two 
groups of disulfides having antifungal activity have been reported.[62-64] The first group of 
compounds contains some of the most potent antifungal agents ever known, the 
thiarubines (56), with MIC’s in the ng/ml range.[62] Isolated as natural products from the 
Compositae (Asteraceae) family of plants, the thiarubines display activities against 
Cryptococcus neoformans, Aspergillus fumigatus, Candida albicans and other species of 
Candida.  
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Figure (1.39). Core Structure of the Thiarubine Group of Antifungals. 
The tunicate-generated disulfide, Citorellamine, not only possesses strong 
antibacterial activity, but is also very active against Saccharomyces cereviae and mildly 
active towards Pseudomonas aeruginosa (Figure 1.31).[51,52] The other group of 
disulfides, the 1,2-dithiole-3-thiones (57a-j), is very interesting because it consists of 
compounds that could possibly behave as a disulfide, sulfide, or thiol in its activity.[63] 
The compounds are fungicidal against Candida albicans, Candida tropicalis, 
Cryptococcus neoformans, Sacharomyces cerevisiae, Aspergillus fumigatus, Aspergillus 
flavus, Aspergillus niger, Microsporum cannis, Microsporis gypseum, Epidermophyton 
floccosum, Trichophyton rubrum and Trichophyton mentagraphytes. The main activity is 
due to the disulfide-thione functionality. Although, the pendant sulfide (thioether) is not 
strictly required for activity[64], its presence, as compared to alkyl or aryl groups, 
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 increases activity greatly. After lengthening the sulfur sidechain beyond ethyl, an inverse 
relationship between chain length and antifungal activity begins to develop. However, 
against all of the fungi tested the benzylthio analogue (57i) maintained the greatest 
potency, with MIC’s ranging from 0.7 to 6.25 µg/ml (Table 1.10). 
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57a R = CH2CH3
57b R = CH2CH2CH3
57c R = (CH2)3CH3
57d R = (CH2)5CH3
57e R = (CH2)9CH3
57f  R = (CH2)11CH3
57g R = CH2C(CH3)3
57h R = Phenyl
57i  R = Benzyl
57j R = Cyclopentyl  
Figure (1.40). Core Structure of the Dithiole-Thione Group of Antifungals. 
 
Table 1.10. Antifungal Activities of Thione Derivatives 57. 
Fungi 57a 57b 57c 57d 57e 57f 57g 57h 57i 57j 
C. albicans 50 25 125 250 >250 >250 >250 50 6.25 100 
C. tropicalis 50 25 125 125 125 >250 >250 12.5 6.25 62.5 
C. neofomans 62.5 12.5 50 62.5 125 125 250 6.25 6.25 50 
S. cerevisiase 50 25 >250 >250 >250 >250 >250 12.5 6.25 >250 
A. fumigatus 50 6.25 50 250 >250 >250 >250 25 6.25 125 
A. flavus 125 25 125 >250 >250 >250 >250 25 6.25 250 
A. niger 125 12.5 125 250 >250 >250 >250 25 3.12 250 
M. Canis 6.25 6.25 6.25 250 >250 >250 >250 3.12 0.7 3.12 
M. gypseum 12.5 12.5 12.5 250 >250 >250 >250 25 0.7 6.25 
E. floccosum 12.5 12.5 12.5 50 >250 250 250 6.25 0.7 6.25 
T. rubrum 12.5 12.5 12.5 50 >250 250 >250 6.25 0.7 6.25 
T. mentagrop. 12.5 12.5 12.5 250 >250 250 >250 25 3.12 12.5 
 
1.4.5 Trisulfides 
 Although not currently used in clinical settings, enediyne antitumor antibiotics 
also display potent antifungal activities. Candida albicans, Ustilago maydis, 
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 Sacchromyces cerisiae, and Neurospora crassa are all inhibited by Calichemicin and 
Namenamicin with MIC’s below 1 µg/ml (Table 1.11).[65] Their mechanism of action is 
presumably similar to that of their antibacterial and anticancer properties as DNA 
cleaving agents triggered by S-thiolation of glutathione or a related thiophile. 
 
Table 1.11. Enediyne Antifungal Activities 
  MIC (µg/ml) 
Fungus Calicheamicin Namenamicin 
C. albicans 0.03 0.25 
U. maydis 0.001 0.004 
S. cerevisiae 0.008 0.06 
N. crassa 0.06 0.25 
 
 
 
 
Isolated from an ascidian, trans-5-hydroxy-4-(4’-hydroxy-3’-methoxyphenyl)-4-
(2’’-imidazolyl)-1,2,3- trisulfide, 42, also displays moderate antifungal activity against 
Candida albicans.[48]
1.4.6 Polysulfides 
 Lissoclinotoxins A (44) (Figure 1.34) and D (58), pyridoacridine alkaloids from 
ascidians, both display potent antifungal activities against Candida albicans and 
Trichosporon mentagraphytes, with cell-mediated immunity levels (CMI) of 40 and 20 
µg/ml, respectively. More moderate activities (CMI’s greater than 40 µg/ml) were 
observed against several other fungi.[66] Pyridoacridines have been shown to intercalate 
DNA and in some cases inhibit topoisomerase II.[66]
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Figure (1.41). Lissoclinotoxin D. 
 
1.5.0 Antiviral Organosulfur Compounds 
1.5.1 Introduction 
For many years the use of antiviral agents in the clinical setting was a dream yet 
to be realized. Now there are a plethora of researchers studying viral pathways, 
discovering new drugs, and delineating novel modes of action. Viruses differ immensely 
from all other classes of infective agents. With no real cell to speak of, a virus consists of 
simply a “shell” or hard protein “coating” that encapsulates viral DNA or RNA. 
“Classical” modes of anti-viral action include the incorporation of “false” DNA building 
blocks, which leads to a blockage of replication, inhibition of the virally-induced DNA 
polymerase (which can be done with some selectivity in relation to the endogenous 
enzyme) inhibition of reverse transcriptase (a virus specific enzyme), inhibition of viral 
protein synthesis, and interference with the “uncoating” process, by which viruses release 
their genetic material. Within this context, organosulfur compounds may play an 
increasingly important role. A recent report shows conclusively that cytomegalovirus 
(CMV), a member of the herpes virus family which can induce mononucleosis-like 
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symptoms in immunocompromised patients, contains free thiol groups which are 
paramount to infectivity.[67] It has been found that if these groups are blocked as 
disulfides the virus is unable to infect, while deblocking the disulfide back to the free 
thiol returns full infectivity. Potentially other viruses may contain similar thiols important 
to their ability to infect, and therein lies the possibility to design novel organosulfur 
compounds for use as antiviral agents. In the search for novel nucleosides with AZT (3’-
azido-3’-deoxythymidine) like activities, a variety of thionucleosides have been 
examined. Here, a sulfur atom occupies the site of the ribose ring oxygen, allowing the 
molecules to be introduced during reverse transcription into viral DNA. A good review of 
the synthesis and biological evaluation of antiviral thionucleoside analogues has been 
published by Wnuk.[68]  
 Although the antiviral properties of garlic natural products are not as highly 
appreciated as their antibacterial effects, Ajoene, Allicin, allyl methythiosulfinate, and 
methyl allylthiosulfinate (Figure 1.16) and Figure 1.18) have all been reported to have 
antiviral activity.[26,69,70] Specifically, these organosulfur compounds show detectable 
inhibitory activity against herpes simplex virus type 1, herpes simplex virus type 2, 
parainfluenza virus type 3, vaccinia virus, vesicular stomatitis virus, and human 
rhinovirus type 2.[70] Ajoene and  allyldisulfide  are also active against human 
immunodeficiency virus (HIV), apparently by inhibiting integrin-dependent processes.[26] 
Integrins are a family of cytokines that provide costimulatory signals to T cells and 
protect them from abnormal cell death. In AIDS patients the action of integrins is 
 impaired by the viral consumption of these T cell protectors. It is interesting to note, 
however, that alliin and S-allyl cysteine have no antiviral activity. 
1.5.2 Thiols 
 Intracellular redox activity plays an integral part in regulating replication and 
infectivity of viruses.[71] The cellular thiol, glutathione, itself has purported in vitro and in 
vivo anti-influenza activity. As levels of glutathione are depleted in the oral, nasal and 
upper airways, susceptibility to viral infection is enhanced. Decreased intracellular 
glutathione levels are also implicated in HIV, and methods to increase glutathione 
production have been proposed as a means to stem these infections.[72] N-Acetyl-L-
cysteine (NAC) and 2-mercaptoethylamine (MEA) have been shown to strongly increase 
glutathione levels in various cell lines.[73] Several new N-(N-acetyl–L-cysteinyl)-S-
acetylcysteamine derivatives (59-61) have also been reported to actively release NAC 
and MEA, which in turn strongly bolsters glutathione levels. 
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Figure (1.42). S-Acetylcysteamines Derivatives 
These compounds display EC90 (effective concentration for 90% inhibition of 
virus yields) ranging from 80 to 380 µM against HIV in human monocyte-derived 
macrophages (MDM).  Organosulfur compounds 60 and 61 with small chain thioester 
moieties are the most active analogues. S-Acylated derivatives are believed to have 
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 increased activity by 1) having a protected thiol and 2) increasing lipophilicity relative to 
the free thiol.  
 Another way reported to protect a free thiol is by use of a thiocyanate, which is 
likely reduced in vivo to the thiol through an equilibrium exchange with a native thiol 
such as glutathione.[74] Examples of this include a group of thiocyanatopyrimidine 
nucleosides (62), which are reported to display reasonable activity (EC75 = 100 µM) 
against vaccinia virus replication in HeLa cells. 
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Figure (1.43). Thiocyanatopyrimidine Nucleoside (R = Ribofuranosyl Nucleoside.) 
 
1.5.3 Disulfides 
 As discussed in relation to antibacterials, organodisulfides can act as in vivo 
oxidants of thiols. It is likely that disulfides, and their related thiosulfonates, behave in 
the same manner in terms of their activity in viral systems. A group of aromatic disulfides 
and a thiosulfonate (63-68) have been reported with potent antiviral activities against the 
arenaviruses Junin (JUNV), agent of Argentine hemorrhagic fever, and Tacaribe 
(TCRV).[75] The disulfides and thiosulfonate displayed 50% effective concentration 
(EC50) values, the concentration where 50% of the virus yield is eliminated, ranging from 
3.6 to 100 µM towards these microbes. This is at least ten times lower than the 
concentrations needed to induce cytotoxic effects.  
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Figure (1.44). Antiarenavirus Disulfides. 
A large focus of preclinical and clinical development of anti-HIV drugs is in 
protease inhibition. However, other processes are certainly important to viral infectivity 
and replication. Metabolic pathways of infected cells, such as precursor protein 
processing, have been shown to be inhibited by a macrocyclic disulfide, 7-methyl-
6,7,8,9-tetrahydrodibenzo[c,k][1,2,6,9]-dithiadiazacyclododecine-5,10-dione (69).[76]  
This compound displays an EC50 of 0.05 µg/ml against HIV-infected 
macrophages. Compared to the current standard AZT that has an EC50 of 0.004. With a 
different mode of action from AZT however, the disulfide acts synergistically with AZT 
when tested in vitro, and could potentially be used in tandem. 
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Figure (1.45). Macrocyclic Disulfide anti-HIV Agent. 
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 Another disulfide with promising antiviral properties is 5,5’-diphenyl-3,3’-
diisothiazole disulfide (DID) (70a).[77] DID induces potent inhibition of plaque-infected 
cells derived from invasion of poliovirus type 1, with an IC50 of 0.35 µM. Cytoxicity to 
healthy human cells was also examined, and no adverse effects were observed with 
uninfected cell cultures at 50 µM concentration of DID. This agent is believed to inhibit 
an enzyme associated with RNA synthesis.  
50% cytotoxic concentrations (CC50), the concentrations where normal cell 
proliferation is inhibited by 50%, were more that 200 times higher that the IC50’s, 
illustrating the exquisite selectivity this compound has for the viral infected cells.[77] The 
reduced form, thiol 70b, has almost the same activity and selectivity as 70a (Table 1.12). 
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Figure (1.46). 5,5’-Diphenyl-3,3’-diisothiazole Disulfide and Thiol Antipoliovirus 
Agents. 
 
Table 1.12. Isothiazole Anti-Poliovirus Activities. 
Compound
IC50
µM 
CC50
µM 
Selectivity  
CC50/IC50
70a 0.35 89.28 255 
70b 0.42 90.75 216 
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  HIV reverse transcription (HIV-RT) and deoxyribonucleoside triphosphate 
(dNTP) synthesis are paramount to viral replication, and thus are prime inhibition targets 
for anti-HIV therapy.[78] A number of sulfur bearing nucleotide HIV-RT inhibitors, which 
have similar effects to AZT, include 3’-mercapto-2’,3’-dideoxynucleotides (71) and 2’-
deoxy-2’-mercaptouridine-5’-diphosphate (72).[79-81] These nucleosides serve to transfer a 
radical to a thiol of the transcriptase as shown in Figure 1.50. A new pyrimidine 
nucleoside disulfide (73) has been synthesized and shown to inhibit both HIV-RT and 
dNTP. The disulfide also has an EC50 of 10 µM and an IC50 of 25 µM against 
proliferation of human T-lymphocyte cells. Very interestingly, the corresponding thiol 
derivative had no activity at all. The mechanism of 73 is thought to involve release of the 
thiryl radical, RSS•, as the primary active species (Figure 1.50).  
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Figure (1.47). Dideoxynucleotides Thiryl Radical-based Reverse Transcriptase 
Inhibitors. 
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Figure (1.48). Mercaptouridine Thiryl Radical-based Reverse Transcriptase 
Inhibitors. 
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Figure (1.49). Nucleosidic Disulfide anti-HIV Agent. 
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Figure (1.50). Proposed Mechanism of Sulfur-bearing Nucleotide-based Reverse 
Transcriptase Inhibition 
Gliotoxin (Figure 1.23), although a somewhat non-specific toxin, is a potent 
inhibitor of poliovirus.[41] Although Gliotoxin has a cytotoxicity which is too high to be a 
useful clinical agent, the compounds antiviral effects warrant further investigation in an 
effort to find an analogue with lower toxicity.  
1.6.0 Antiparasitic Organosulfur Compounds 
1.6.1 Introduction 
 As with all three of the previously discussed types of infections, bacterial, fungal 
and viral, garlic extracts have been known the longest to exhibit antiparasitic properties. 
Generally, the most serious of these infections involve invasion of the intestinal tract or 
other internal organs. Since these microbes generally have low intracellular glutathione or 
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 trypanothione concentrations they are proposed to have a higher sensitivity toward sulfur 
anthelmintics compared to mammalian cells.  
 Allicin (Figure 1.16) has been tested against a number of protozoan parasites, 
Giardia lamblia, Leishmania major, Leptomonas colosoma and Crithidia fasciculata, and 
determined to have MIC50 values equal to about 30 µg/ml. Toxicity levels toward tissue-
cultured mammalian cells of Allicin is above 100 µM.[69] Allicin has also been reported to 
display potent inhibition of Entamoeba histolytica, with complete inhibition at 30 µg/ml 
and an IC90 of only 5 µg/ml.[82, 83]  
Diallyl trisulfide, 17, which Allicin has been shown to degrade to in situ, also 
shows potent inhibition of Entamoeba histolytica with an IC50 equal to 14 µg/ml.[27] 
Diallyl trisulfide displays the same MIC’s against Giardia lamblia and Trypanosoma 
species (Table 1.13).[84]  
 
Table 1.13. Growth Inhibition (IC50) Activities of Dasuansu (Diallyl Trisulfide (17)) 
Against Parasites.[26]
 Parasite IC50(µg/ml) 
Trypanosoma brucei brucei 2.5 
T. b. gambiense 1.8 
T. b. rhosesiense 2.9 
T. evansi 0.8 
T. congolense 5.5 
T. equiperdum 1.2 
Entamoeba histolytica 59 
Giardia lamblia 14 
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  Ajoene (Figure 1.18) inhibits the proliferation of both epimastigotes and 
amastigotes of Trypanosoma cruzi, the causative agent of Chagas' disease.[84] Ajoene 
alters the composition of phospholipids, most likely through a sulfenylation that inhibits 
the phosphatidylcholine biosynthesis and cell proliferation. A 40 µM concentration of 
Ajoene is all that is required to eradicate the parasite, in amastigote form, from host cells 
in 96 hours, while an 80 µM concentration is enough to immediately inhibit growth in the 
epimastigote form. Ajoene is also cytocidal to epimastigotes at 100 µM within 24 hours. 
As well, an entire host of garlic extracts, methyl propyl sulfide, allyl 
methylsulfide, diallyl sulfide, dimethyl sulfide, diallyl disulfide, dimethyl disulfide, 
methyl propyl disulfide, allyl mercaptan and dipropyl disulfide (some in Figure 1.16), 
have been tested separately against Giardia intestinalis, displaying IC50 values ranging 
from 100 to 1300 µg/ml (Table 1.14).[85]  
 
Table 1.14. Antiprotazoal Activity of Garlic Extracts. 
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 1.6.2 Thiols 
 A novel sesquiterpene named T-cadinthiol (74), also shows significant 
antiparasitic properties.[86,87] This terpenoid metabolite, with four fixed stereocenters, 
displays activity towards cultured Plasmodium falciparum, a species of malaria, with an 
IC50 of 3.6 µg/ml. The mode of action of this agent is still unexplored, however, and a 
number of derivatives of 74, including the corresponding alcohol analogue, were tested 
and shown to have absolutely no biological activity. The thiol group appears to be 
essential for anti-parasitic effects. 
H
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Figure (1.51). Antiprotazoal Agent T-Cadinthiol. 
Until the availability of Cymelarsan (75) (melarsamine hydrochloride), treatment 
of African trypanosomiasis had relied heavily on antiviral agents which have a number of 
strong side effects. A successful attempt to increase the activity of this drug, by 
derivatizing the thiol groups to get the level of affinity between arsenic and sulfur atoms 
optimal for biological activity, has been reported.[88] The most active thiol system is the 
propane-1,3-dithiol (76) (2-melarsenyl). In fact, 2-merlarsenyl is twice as potent as 
Cymelasan against Trypanosoma brucei brucei strains (0.025 versus 0.05 µM 
concentration to terminate all growth in 1 hour). It is believed that in aqueous solution 
Cymelasan is in equilibrium with the hydrolyzed oxide form (melarsen oxide), which has 
lost one thiol group and thus half the activity.[89]
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Figure (1.52). Typanocidals Cymelasan and 2-Melarsenyl. 
 
1.6.3 Sulfides 
Fasciolosis (Fasciola hepatica) is a serious parasitic disease in humans and 
livestock. Few new anti-fasciolitic compounds have been marketed since triclabendazole 
(TCBZ), a benzimidazole used routinely in veterinary medicine since 1983 and for 
human use, in some regions, since 1989, was patented in 1978.[90] A new bioactive 
derivative of TCBZ, 5-chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole (77) 
has been recently discovered.[91] While this analogue has an effective dose of 15 mg/kg 
with 100% effectivity, the marketed TCBZ displays a 5 to 10 mg/kg effective dose 
against Fasciola hepatica. The mechanism of action of this analogue has not been 
elucidated, and the role of the sulfide moiety is not known. 
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Figure (1.53). A Methylthiobenzimidazole Fasciolicide 
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1.6.4 Pentasulfide 
 Another anti-malarial agent, Lissoclinotoxin A (45), has demonstrated potent 
activity towards a resistant strain of the parasite Plasmodium falciparum.[55]  
Lissoclinotoxin A is intermediate in activity compared to the usual antimalarials quinine, 
mefloquine, halofantrine and chloroquine, with an IC50 of 296 nM (Table 1.15). Although 
not yet defined conclusively, its mechanism is likely similar to that described for di- and 
trisulfide antibacterials. 
 
Table 1.15. Anti-Malarial Activities of Lissoclinotoxin A and a Few Clinical 
Standards. 
Anti-Malaria Agent 
IC50 
(nM) 
Lissoclinotoxin A (45) 296 
Quinine 350 
Mefloquine 40 
Halofantrine 2 
Chloroquine 580 
 
1.7.1 Conclusions & Future Prospects 
 Garlic formulations have been used for thousands of years for the treatment of 
many types of infections. We now know that the attributable anti-infective effects are 
caused by the active organosulfur species within. The failure to commercialization these 
compounds most likely stems from their volatility and instability. However, other active 
sulfur reagents have been discovered, or synthesized, which have similar or better 
biological activities with good stabilities and very low vapor pressures. Numerous sulfur 
compounds are yet to be evaluated for biological activity. The precise targets and modes 
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of action of many sulfur reagents are still unexamined. It has been proposed that the thiol-
disulfide redox metabolisms of infectious organisms might serve as a potentially valuable 
target for development of new anti-infectives.[11] For decades, no new targets have been 
discovered and brought to bear in clinical usage, even though these systems are essential 
for pathogenic growth and viability. The rapid procession of resistance to available 
antimicrobials, which target essentially three types of cell processes (cell wall synthesis, 
protein synthesis, and DNA synthesis), is depleting the current arsenal of antibiotics that 
remain effective. Often, these redox systems are extraordinarily divergent from 
mammalian physiology and therefore provide targets where selectivity should be very 
easy to come by. Stripping these infectious agents of their natural antioxidants will leave 
them wide open to the stresses of the external environment, or cause them to invest 
significant resources to develop resistance mechanisms for survival. Therefore 
compounds that recognize these systems should be excellent drug candidates. The genes 
for these systems, in a number of microbes, have been cloned and sequenced. 
Imaginative, novel designs and development of new structural classes of anti-infective 
agents, with the intention of affecting these thiol-disulfide redox systems, is a rational but 
nearly unexplored avenue of drug discovery and is the focus of this dissertation.  
 An introduction of classical antibiotics follows in Chapter 2. The detailed organic 
synthetic methodology used to generate this new class of β-lactams is provided in 
Chapter 3. An explanation of how N-thiolated β-lactams have been found to be active 
organosulfur agents against bacteria, such as Staphylococcus and Bacillus, fungi such as 
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Candida, and even neoplasmic systems, such as those related to leukemia and cancerous 
tumors, then follows in Chapters 4 through 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER TWO 
DEVELOPMENT OF ANTI-MRSA AND ANTI-ANTHRAX ANTIBIOTICS 
 
 
2.1.1 Introduction 
Staphylococcus aureus, a species of bacteria which is often referred to as "staph", 
can live harmlessly on many skin surfaces, especially around portals such as the nose, 
mouth, genitals, and rectum. But when the skin is punctured or broken for any reason, S. 
aureus can enter the wound and cause an infection. S. aureus can cause folliculitis, boils, 
scalded skin syndrome, impetigo, toxic shock syndrome, cellulitis, and other types of 
infections. After the discovery of penicillin (78) by Alexander Fleming in 1928, the 
elucidation of a crystal structure by Hodgekins and Rodgers-Low, and the scale-up 
production processes of Flory and Chain, S. aureus infections became very treatable by 
penicillin, and eventually by a variety of penicillin analogues 78-82.  
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Figure (2.1) Penicillin analogues.  
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 During the 1960’s and 70’s a number of other β-lactam antibiotic classes, with the 
ability to inhibit growth of S. aureus as well as other bacteria, were either discovered 
from natural sources or generated via synthetic manipulations (2-4,83-86). 
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Figure (2.2) Common Classes of β-Lactam Antibiotics.  
Unfortunately, the efficacy of these drugs has steadily declined since their initial 
conception, due to the ability of S. aureus to acquire resistance mechanisms. Methicillin, 
a standard lactam for measuring resistance, resistant Staphylococcus aureus (MRSA), is 
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 a multi-drug resistant bacteria whose immunity to antibiotics was first discovered in 1961 
(only one year after clinical introduction of methicillin).[93] The percentage of S. aureus 
strains with resistance to standard β-lactam antibiotics has doubled over the past fourteen 
years, from 30% to 60% as seen in Figure 2.3.  
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Figure (2.3) Increase of S. aureus Resistance, as Reported by the Centers for Disease 
Control (CDC). 
The classical method of MRSA infection is acquisition during unrelated 
treatments in a hospital setting. For example, a patient may visit a hospital for a puncture 
wound and become infected with MRSA. With low drug efficacies against these 
infections, it often becomes quite difficult to treat MRSA. Even other types of antibiotics, 
such as Vancomycin, considered the last line of defense against MRSA, are now 
exhibiting lower efficacy levels due to acquired resistance. 
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Recent headlines are providing additional urgency to develop new antibiotics for 
the treatment of resistant infections, as reports have come out that MRSA is no longer 
constrained to the hospital setting. This year a large number of the MRSA infections 
reported included infections acquired in the community. A group of novel drugs, whose 
mode of action are not affected by current resistance pathways, are therefore in high 
demand as this scourge is becoming untreatable. 
 Bacillus anthracis (Anthrax) has also received much attention, in recent years, as 
a matter of national security. Currently the most effective antibiotic for this infection is 
Ciprofloxacin (Cipro). Generating more, equally potent, defenses against this potential 
terrorist weapon is certainly an appropriate goal in light of the evolution of drug 
resistance seen in other bacterial systems. This chapter will focus on the development of 
antibiotic agents for MRSA and Anthrax, and on investigations into their modes of 
action. 
2.2.1 β-Lactam Antibiotics: Anti-MRSA 
 Penicillins and Cephalosporins have disputably been the most clinically important 
group of compounds discovered to date. Extensive investigations have led to a clear 
picture of biosynthesis and antibacterial modes of action.  
The biosynthetic pathway of penicillin begins with the condensation of L-
aminoadipic acid (87), L-cysteine (88) and L-valine (89) via δ-(L-α-aminoadipyl)-L-
cysteinyl-D-valine (ACV) synthetase to form a tripeptide intermediate (89) with 
epimerization at the α-carbon of the valine residue.  
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Figure (2.4) Open ring Penicillin Biosynthetic Intermediate. 
Next, is the annulation of the bicyclic core skeleton to isopenicillin N (IPN) (91), 
by what else but IPN synthase, followed by epimerization of the α-aminoadipoyl α-
carbon, by IPN epimerase, to provide penicillin N.  
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Figure (2.5) Annulation and Epimerization of Open ring Lactam. 
Need a cephalosporin? Ring expansion and hydroxylation of penicillin N, by 
deacetoxycephalosporin C/deacetyl cephalosporin C (DAOC/DAC) synthase(s), 
effectually produces deacetyl cephalosporin C (92) from penicillin N. 
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Figure (2.6) Ring Expansion and Hydroxylation to Deacetyl Cephalosporin C. 
 Penicillins are well known for there mode of action involving the coupling with 
penicillin binding proteins (PBP’s). In this manner, penicillin antibiotics kill bacteria by 
disrupting cell wall synthesis and as effected cells attempt to expand they become 
deformed or even lysed. Simply speaking, penicillin binds to a serine residue of the 
transpeptidase enzyme (the primary enzyme of cell wall crosslinking), irreversibly, and 
inhibits that enzyme from being involved in cell wall crosslinking. Like a broken link in a 
chain, this results in a malformed peptidoglycan network and thus deformed or lysed 
cells. Without this strong crosslinked network, ordinary osmotic pressure within the cells 
can cause them to rupture. 
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Figure (2.7) Penicillin’s Interaction with PBP’s. 
Due to widespread over usage, β-lactam antibiotics continue to succumb to 
developed resistance. Researchers have had great success synthesizing new lactam 
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 derivatives to combat resistance. However, none of these is immune to the cell defense 
enzyme β-lactamase, except the N-thiolated β-lactams (93) (Chapters 3 through 6).  
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Figure 2.8 N-Thiolated β-Lactam Antibiotics. 
Despite the continuous increase in resistance to multiple analogs of 
cephalosporins and penicillins, these drugs remain the most abundantly prescribed class 
of antibiotics. Primary resistance to these antibiotics is related to cleavage of the β-lactam 
ring by a specialized bacterial defense enzyme that is released extracellularly, β-
lactamase. β-Lactamase interacts with the lactam ring in much the same way as PBP’s do, 
by breaking open the four membered ring. This ring opened form does not inhibit cell 
wall synthesis or disrupt any other cell function. So, in effect, the drug is deactivated by 
formation of the lactam-lactamase adduct, before it can reach the transpeptidase target. 
Except in the case of N-thiolated β-lactams, this weakness is ubiquitous amongst β-
lactam antibiotics due to the extreme lability of this strained ring system. Again, the N-
thiolated β-lactams are unaffected by β-lactamase and are discussed in greater detail in 
the following chapters. 
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Figure (2.9) β-Lactamase Ring Opening of Penicillin.  
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2.3.1 Vancomycin and the Peptide Antibiotics 
 Vancomycin (94) is the most successful clinical treatment for MRSA infections 
thus far. Like the standard β-lactam family, this antibiotic acts by interrupting cell wall 
synthesis, albeit in a different way. Part of a family of peptide antibiotics, the 
glycopeptides, Vancomycin is a potent antibacterial agent which, unlike ordinary β-
lactams, is impervious to β-lactamase defenses. However, bacteria with specific defenses 
that can deactivate Vancomycin have developed over the course of time. The first of 
these was from a strain of enterococci, now termed Vancomycin resistant enterococci 
(VRE). The resistance has since jumped, via a plasmid, to S. aureus, alerting a need for 
new antibiotics to fight this cross-resistance. Synthetic modifications have successfully 
defeated VRE and Vancomycin resistant strains of S. aureus (VRSA), however 
development of strains with resistance to these analogues is bound to occur. Other 
peptide antibiotics, depsipetides and lipopeptides, are reported to display potent activities 
against VRSA, but are, as of yet, not clinically available. 
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Figure (2.10) Vancomycin. 
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Figure (2.11) Teicoplanin, an Example of a Semi-synthetic Analogue of Vancomycin. 
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 2.4.1 DNA and Protein Synthesis Inhibiting Antibiotics 
 Although DNA synthesis inhibition or the cleavage of fully formed DNA are 
accepted targets of antibacterial exploitation, there currently are no clinically available 
analogues. One group of promising DNA synthesis inhibitors are the coumarins. These 
type II topoisomerase inhibitors have shown great selectivity in targeting DNA gyrase[96]. 
X-ray crystallographic analysis of a 24-kDa N-terminal fragment of DNA gyrase with 
bound novobiocin (96), a typical coumarin, reveals that the antibiotic binds competitively 
at the ATP site and that the aminocoumarin bicyclic ring is the scaffold for presenting the 
L-noviosyl sugar moiety to interact with the gyrase.[97]
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Figure (2.12) Novobiocin. 
 Linezolid (97, trade name Zyvox), an oxazolidinone, is a fairly recent addition to 
the clinically available arsenal of antibiotics known to affect S. aureus. Most, 
oxazolidinones are protein synthesis inhibitors by irreversible binding to ribosomes. 
Their bacteriostatic activities are most pronounced amongst Gram-positive bacteria. 
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Figure (2.13) Linezolid. 
 
2.5.1 Anthrax 
 Bacillus anthracis, Anthrax, was once a common problem amongst people and 
cattle. With the advent of antibiotics like penicillin, doxycycline, and amoxicillin this 
scourge was all but wiped out. Unfortunately, Anthrax has now become a weapon which 
is popular amongst terrorists. While, these antibiotics can be very effective against 
susceptible strains, a better defense has been developed, Ciprofilaxin (98). Ciprofilaxin 
retains potent activity against most strains of anthracis and even acts effectively as a 
prophylactic treatment for suspected exposures. However, resistant strains are emerging. 
A nalidixic acid-resistant strain of anthracis has already been discovered with a 10-fold 
lower susceptibility to Ciprofilaxin than other strains.[98] Therefore, it is equally 
important to find antibiotics with a novel mode of action which impedes induction of 
resistance amongst these bacteria. 
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Figure (2.14) Ciprofilaxin. 
 
2.6.1 Conclusions 
 For a number of years, pharmaceutical companies all but abandoned the search 
for new antibiotics, out of complacency. Now, as the advent of resistant bacteria is on a 
steady climb, researchers, industrial and academic, are coming back into this area of 
research.  While new derivatives of currently available drugs seem to be a quick-fix, 
agents with entirely novel modes of action must be discovered to establish a more 
permanent solution to the ever-present problem of antibiotic resistance.  
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CHAPTER THREE 
N-ORGANOTHIOLATED β-LACTAMS: SYNTHESIS  
 
3.1.1 A Brief History 
 Since Alexander Fleming’s discovery of penicillin in 1928, β-lactam antibiotics 
have developed into the most profound medical discovery to date. Though, it was not 
until 1940 that Florey and Chain showed penicillin’s value as a potent systemic 
antibacterial agent. Fortunately, this discovery came just in time to be of use during 
World War II, thus saving many lives. Although bacterial resistance was already rearing 
its ugly head just a year after penicillin’s introduction, it was not until the 1960’s that a 
multitude of β-lactam analogues, to defeat these resistant microbes, were either 
discovered from natural products or developed synthetically, as discussed in Chapter 2. 
Most structurally related to the N-thiolated β-lactam project is the first monocyclic class 
of β-lactam antibiotics, the monobactams (discussed in chapter 2). Mechanistically 
however, these agents are drastically different from N-thiolated β-lactams. The N-
thiolated β-lactams are truly a novel class of antibiotics, separate from penicillins, 
cephalosporins, carbapenams, penams and monobactams, not only by structural 
differences but also in their mechanisms of antibacterial activity (as will be shown in 
chapter 5). 
In earlier studies an N-sulfenylated β-lactam (99) was isolated on synthetic route 
to the generation of novel isopenems (100).[99] Testing this intermediate against a panel of 
 microbes revealed potent inhibition of an array of bacteria, including MRSA. This 
sparked our laboratory’s interest in studying N-thiolated monocyclic β-lactams.  
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Figure (3.1) Discovery of Novel N-Substituted Monocyclic β-lactams. 
3.2.0 Synthesis Towards an SAR 
3.2.1 Introduction 
 With five possible sites of substitution on the lactam ring, two at C3 (R2 & R3), 
two at C4 (R4 & R5) and one at N1 (R1), a large variety of variations could be explored as 
long as they are synthetically feasible (Figure 3.2).  
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Figure (3.2) β-Lactam Substitutions  
Initial structure-activity studies focused on determining the importance of the C4 
substituent.[100] Although monocyclic β-lactams have antimicrobial activity with their 
monocyclic form, certain amido functional groups are required for their activity. 
However, substitutions at either C3 or C4 on these N-thiolated monocyclic β-lactams 
demonstrated no prominent effect on antimicrobial activity.[100] Activities were different 
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for various substitutions at these loci, but the absence or presence of saturation levels or 
functional groups did not turn activity on or off like a switch. So, for all intense purposes, 
variation of substituents at sites R2 through R5 does not radically affect antibacterial 
activity. For example, changing the substitution of R2 from a methoxy group to an 
acetoxy group has almost no effect. As long as there is some electronegative group at R2 
or R3, activity does not seem to change drastically. In fact, with no substituent at C3, 
antibacterial activity still persists. As well, a variety of different halo-substituted aromatic 
functionalities R5 affords very little flux in antibacterial activity. As long as an 
unsaturated group or electronegative element exists at C4 antibacterial activity changes 
very little. Lipophilicity can assist N-thiolated β-lactams though, as demonstrated by 
better bioactivities for derivatives having longer C3 side chains.[100] However, total 
absence of this side chain results in a compound which still maintains potent biological 
activities. 
This led me to believe that activity had a greater dependence on some other 
structural motif than these side chains. Substitution at R1, indeed, is paramount to activity 
(Table 3.1). Without an appropriate functional group at this position biological activity is 
non-existent. The focus of this chapter will be the synthesis of varied N-substituted β-
lactams for the SAR which follows in the next chapter. 
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N
O R1
R2 R3
R1 R2 R3
Antibacterial 
Activity 
S-CH3 O-CH3 Alkyl +++ 
S-CH3 O-CH3 Aryl  +++ 
S-CH3 O-CH3 Alkenyl +++ 
S-CH3 O-CH3 Alkynyl +++ 
S-CH3 O-CH3 Propargylic +++ 
S-CH3 O-CH3 Ester +++ 
S-CH3 O-C(O)CH3 Aryl  +++ 
S-CH3 O-Ph Aryl  +++ 
S-CH3 H Aryl  +++ 
S-CH3 S-Bn Alkynyl +++ 
S-CH3 O-C(O)CH3 Alkynyl +++ 
S-CH3 Phthalimido Alkynyl +++ 
H O-CH3 Alkynyl --- 
Cl O-CH3 Alkynyl --- 
Se-Ph O-CH3 Alkynyl --- 
 
 
+++ = Active 
--- = Inactive 
 
 
 
 
 
Table 3.1 Effect of β-Lactam Substitutions on Antibacterial Activities. 
3.2.2 Synthetic Strategy 
 The synthesis of these N-thiolated β-lactams, like that in Figure 3.3, is comprised 
of two major steps. First, the annulation of the β-lactam ring from an acid chloride and 
imine. Secondly, N-thiolation (or sulfenylation) of the β-lactam nitrogen. 
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Figure (3.3) Retrosynthetic Analysis 
 Closer inspection of the standard synthetic steps towards N-thiolated β-lactam 
syntheses reveals a few additional nuances (Figure 3.4). First is the generation of an 
appropriate acid chloride. Variation of the acid sidechain will directly translate to a 
 variation in the identity of the functional groups at C3. Next, a simple synthesis of an 
imine is performed by the addition of para-anisidine with an aldehyde of choice. Here, as 
well, choice of the starting material translates directly into an β-lactam substitution 
pattern, for whatever side groups are attached to the chosen imine will become the 
substituents at C4. With these coupling agents in hand, the aforementioned annulation 
occurs by a Staudinger type coupling to generated an N-protected β-lactam. Deprotection 
(or dearylation) is induced to generate the N-protio β-lactam. Finally, N-thiolation occurs 
readily with an appropriate transfer reagent. Greater detail follows in the subsequent 
sections. 
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Figure (3.4) Standard Synthetic Overview 
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3.2.2 Acid Chloride Synthesis 
 Although some of the necessary acid chlorides were available for purchase, the 
low purity and moderately high expense made the synthesis of these reagents more 
attractive. The synthesis of these acid chlorides is simple and straight forward. Since the 
free acids were inexpensive and of relatively high purity upon purchase, they were used 
without further purification. The activating agent, thionyl chloride, was always racked 
with impurities such as sulfates and sulfoxides. A two step distillation process, with the 
use of linseed oil, proceeded to produce fairly pure thionyl chloride. This was then 
immediately used after purification. In most cases the resulting acid chloride required 
purification via one last fractional distillation. 
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Figure (3.5) Acid Chlorination 
3.2.3 Imine Synthesis 
 N-(2-Chlorobenzylidene)-4-methoxybenzenamine (105) was easily prepared via 
the condensation of 2-chlorobenzaldehyde (103) and 4-anisidine (104). Both reagents, 
however, required purification before use, even when newly purchased. The amine (105) 
was recrystallized from water and dried under reduced pressure. Aldehyde (103) was 
purified via atmospheric distillation.  Originally the reaction was commenced by 
dissolution of 4-anisidine in freshly distilled methylene chloride, followed by pipette 
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 addition of 2-chlorobenzaldehyde. It was later discovered that the presence of the solvent 
was completely unnecessary. Later reactions were performed by simple addition of (6) to 
(5). In the solvent free methodology a significant portion of released thermal energy 
could be observed. Camphorsulfonic was added in a few instances to trigger the 
condensation, however this was usually unnecessary. In either case, long, sharp, bright 
yellow crystals of product were formed along with an equivalent amount of water. A spot 
to spot conversion could also be followed by thin layer chromatography (TLC), but 
reaction completion was rarely of doubt. Proton nuclear magnetic resonance (1HNMR) 
spectroscopy was used to confirm complete formation of the imine. 
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Figure (3.6) Imine Formation 
3.2.4 Staudinger Coupling 
 The Staudinger coupling is a formal [2+2] cycloaddition process of an acid 
chloride (102) and a Schiff base, imine (105). The Staudinger coupling is the most 
prevalent method of monocyclic β-lactam formation and it is successfully used to prepare 
N-protected lactam (106). In this case, a ketene-mediated cycloaddition is believed to be 
on of the possible mechanisms of annulation, versus a direct acylation of the imine. 
Ketene formation is initiated via deprotonation by a Bronsted-Lowry base, triethylamine 
or diisopropylethylamine (Hunig’s base). This solution is normally refluxed in freshly 
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distilled methylene chloride for 12 to 24 hours and closely monitored by TLC.  The 
product obtained always demonstrated the cis relative stereochemistry, although this is 
not the case under modified conditions. In the case of Figure 4.3 the imine used is always 
of the E-configuration which ultimately leads to the cis formation if the cyclization is 
truly [2+2]. It is possible, for the cases where a trans substituted lactam is formed via a 
Staudinger coupling, that either a Z-imine was used or a potent nucleophile can interrupt 
the cyclization and allow free rotation of the imine unsaturation. All of these steps are 
part of an equilibrium, therefore it is also possible that the lactam ring may reopen and 
interconvert between forms. Regardless of the mechanistic pathway, this cyclization 
always provided a racemic mixture of cis diastereomers. Exploration of the properties of 
each separate diastereomer is detailed in later sections.  
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Figure (3.7) Possible Staudinger Coupling Mechanisms 
3.2.5 Dearylation 
 A procedure was reported in the literature which effectively deprotects lactam 
(106) by oxidative cleavage of the N-methoxyphenyl carbon-nitrogen bond.[87] In this 
case, ceric ammonium nitrate (CAN) is used as the oxidant in an aqueous acetonitrile 
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 solution. CAN initiates a radical mechanism which results in a di-hydroxylated, pre-
quinone form. Washing with a mild reagent, such as sodium bisulfite, drives the reaction 
to completion with generation of the protonated lactam (107) and one equivalent of 
benzoquinone (108). In small scale reactions, less than 2 grams, dearylation with three 
equivalents of CAN proceeded, at zero degrees Celsius, in moderate yields within 10 
minutes. Larger scale reactions also proceeded within 10 minutes, however yields 
suffered significantly at these larger quantities. Once the reaction was determined to be 
complete, by TLC, the reaction mixture was poured into water, extracted with ethyl 
acetate, washed with sodium bisulfite and sodium bicarbonate, dried over magnesium 
sulfate and concentrated via rotary evaporation. Attempts to increase yields with 
extended reaction times, variations in temperatures or different stiochiometric ratios 
failed to provide any benefit. 
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Figure (3.8) Dearylation. 
3.2.6 N-Substitution: Basis for the Phthalimide Transfer Reagent 
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 A series of sulfenyl, sulfinyl, and sulfonyl analogues was synthesized using N-
thiolating reagents and some direct modifications.  Extremely important to the thiolation 
of the monocyclic β-lactams is an organothio-transfer reagent, the N-thiolated 
phthalimide. More direct methods failed to succeed (Figure 3.10). What seemed like the 
 most direct method was to first generate the sulfenyl chloride which could then be 
attacked by the deprotonated β-lactam nitrogen. However, this resulted in opening of the 
lactam ring, as crude 1HNMR spectra show absolutely no lactam ring protons. The most 
likely culprit for opening the ring in this case is the ejected chloride anion. Once the 
sulfur is installed, it is very plausible that the chloride anion could act as a nucleophile, 
attacking the carbonyl of the ring and forcing the ring to cleave between the carbonyl-
carbon and nitrogen bond, although this was never isolated. Regardless of conditions, this 
pathway yielded no product, yet consumed all of the N-protio lactam starting material. 
 A gentler method was then attempted where the sulfenyl chloride was first reacted 
with deprotonated succinimide to generate the N-thiolated succinimide. This reagent 
transfers the organothiol group to the lactam with extremely poor yields, below usable 
limits. However, no lysis of the lactam ring occurred, making this pathway somewhat 
better than direct introduction using sulfenyl chlorides.  
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Figure (3.9) Failed Direct N-Organothiolation Method. 
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Figure (3.10) Failed Transfer N-Organothiolation Method. 
The best method for sulfenylating the lactam-nitrogen was via another transfer 
reagent 111 made from phthalimide. A number of organothiol groups could be 
transferred to the lactam with this type of reagent, whether by using a tertiary amine or 
carbonate base.  
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Figure (3.11) N-Organothiolation Methods. 
Synthetic pathways where a sulfur functionality is already installed on the imine 
prior to annulation may be plausible for some trityl systems, however this method was 
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 completely ineffective here.[101] Although often problematic, thio-transfer seems to be the 
best method, as shown in Figure 3.11. 
Most thiols can be chlorinated in a straight forward manner by dissolution in a 
benzene solution which contains an equimolar quantity of dissolved chlorine gas. This 
sulfenyl chloride solution can then be added, in situ, to a preformed slurry of Hunig’s 
base and phthalimide in ice cold benzene. As the reaction proceeds and the thiolated 
phthalimide 111 is formed, the mixture dissolves into a clear solution. Unreacted 
phthalimide 112 remains as a solid and can be easily filtered off. After aqueous workup 
with solutions of bicarbonate, bisulfite and saturated salt, the dried and concentrated solid 
can be easily purified via recrystallization from ethanol. For cases which did not proceed 
smoothly via this route, greater success could be found via reaction of the thiol with N-
bromo phthalimide reagent 113. This method brought higher yields to reactions with 
longer chain thiols. 
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Figure (3.12) Phthalimide Synthesis. 
The yields for the synthesis of N-thiolated phthalimide reagents bearing large aryl 
substituents were increased by using potassium carbonate and sonication rather than 
Hunig’s base or sodium hydride. Likewise, some N-thio phthalimides could be formed by 
first oxidizing the thiol to the thiosulfone via mCBPA, which is more easily attacked by 
phthalimide. Alkyl and aryl substituents were attainable through these routes, however, 
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 great resistance was confronted with all attempts to install sulfurs of different oxidation 
states or hetero-groups on the thiol side chain. 
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Figure (3.13) Alternative Phthalimide Synthesis Routes. 
Synthetically, the N-octylthiolated 109e lactam was extraordinarily challenging at 
the phthalimide transfer reagent synthesis step. More than 10 sets of conditions were 
attempted before any N-octylthiophthalimide was observed, and even in this one case the 
yield was extremely poor, as the equilibrium between octylthiol and 1,2-dioctyl disulfide 
heavily favored the disulfide. The yield was improved by mCPBA oxidation of the 
disulfide to the thiosulfonate, making the chlorination and addition to phthalimide easier.  
The N-butylthio lactam 109d was generated quite simply using N-
bromophthalimide with n-butylthiol and triethylamine, where the other three analogues 
were synthesized in the highest yields from the chlorinated thiol via addition of chlorine 
gas to the thiols, followed by addition of phthalimide and a tertiary amine base. 
Also, transfer of organothio-groups from the phthalimide to the lactam was 
seriously hindered by steric bulk. Although phthalimide transfer reagent synthesis was 
achieved for highly hindered organothio systems, anything larger or more branched 
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 proved difficult to transfer to the lactam by this method. sec-Butylthio and tert-butylthio 
groups were successfully installed, but with difficulty. Phthalimide reagents which were 
either unsuccessfully prepared, as with the branched alkyl chains, or were prepared but 
unsuccessfully used to make the corresponding β-lactam derivatives, as with the 
heteroatom containing sidechains, are shown in Figure 3.14. 
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Figure (3.14) Unsuccessful Phthalimide-based Transfers. 
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As described, most of the N-organothio phthalimides were prepared via 
chlorination of the corresponding thiol or disulfide to generate the sulfenyl chloride in 
situ and then added dropwise into a chilled flask containing phthalimide, and 
triethylamine or Hunig’s base. After purification by flash chromatography the 
phthalimide reagents (111) were then added to an equimolar quantities of N-protio β-
lactam (108) and an amine base, usually Hunig’s base or triethylamine, and refluxed in 
dry methylene chloride or benzene for 1 to 10 days. After aqueous workup with solutions 
of bicarbonate, bisulfite and saturated salt, the resulting phthalimide was removed via 
trituration with chloroform. Residual organothiolated phthalimide was removed, 
painstakingly, via column chromatography.   
3.3.1 Asymmetric Synthesis 
Of course not all of the desired thiols or disulfides needed for these studies were 
commercially available. For example, when this project was initiated enantiomerically 
pure thiols were unavailable and enantiomerically pure alcohol precursors were cost 
prohibitive. So, the first method attempted to generate enantiomerically pure thiols 
involved enzymatic resolution of esters 114 via Lipase PS-30, a generous gift from the 
Amano enzyme company. In a slightly less than pH 7 buffered solution, complete 50:50 
resolution of racemic esters could be accomplished in about a week.  After filtration 
through Celite, the alcohol 115 and unaffected ester 116 were separated via column 
chromatography. Mitsunobu coupling of 115 and acetylated 116, however, to afford 117 
and 118 did not proceed so smoothly. Steric hindrance was a serious problem for these 
secondary centers, forcing the crude yield to be quite low. Though a similar literature 
 procedure exists for the thioester formation starting from 2-nonanol, the shorter chain 
analogues proved to be much more difficult to purify due to their volatility. Reduction of 
the thioester to the free thiol (119 and 120) also proved problematic. While some 
conversion occurred, the volatility of the thiol product made purification impossible 
(Figure 3.16).  
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Figure (3.15) Initial Enzymatic Scheme Towards Enantiomerically Pure Thiols. 
Next, a pathway was tried which involved a chirality inducing, nicotine based 
rearrangement process.[95] The first step of this process involved the hydride assisted 
attack of racemic 2-butanol 121 on carbon disulfide, which in turn activated attack on 
methyl iodide to form dithioate 122. Rearrangement of this sec-butyloxy-dithioate 122 to 
the sec-butylthio-dithioate 125 proceeded via a dioxy-(S)-(-)-nicotine reagent 124 (from 
oxidation of 123 via mCPBA). Unfortunately, the following reduction step suffered 
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 similar problems of low yields. Purification was again made impossible by the extreme 
volatility of the product thiol 119.  
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Figure (3.16) Nicotine Based Scheme Towards Enantiomerically Pure Thiols. 
At this point, attempts to obtain enantiomerically pure sec-butylthiol were 
abandoned in favor of a less volatile system such as 2-phenylethylthiol. Beginning with 
the acetic ester 126, Lipase PS-30 was used again for enzymatic resolution. This worked 
very well. After filtration and concentration, purification simply involved the separation 
of the two layers, alcohol 127 and unaffected acetic ester 128. Unfortunately, this is as far 
as this pathway would proceed, for the subsequent Mitsunobu substitution on the alcohol 
would not take place at any appreciable level to generate enough product (129 and 130) 
for purification. 
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Figure (3.17) Second Enzymatic Scheme Towards Enantiomerically Pure Thiols. 
The ability to generate the enantiomerically pure alcohol 127 suggested that it 
may provide a way to produce the enantiomerically pure thiol.  This pathway was first 
tested with a racemic mixture of 2-phenylethanol (131), which is easier to handle than the 
more volatile, more soluble 2-butanol (Figure 3.18). Chloride substitution of the alcohol 
with thionyl chloride was straightforward and proceeded smoothly. This reaction was 
assumed to go through an SN2 process to afford the stereochemically-inverted chloride 
132. Thioesterification also proceeded smoothly by a second nucleophilic substitution 
with thiolacetic acid to generate thioester 133. Next, a one-pot, two-step procedure 
produced the N-thiolated phthalimide 134, without any free thiol intermediate.[84] The 
first step involves the sulfuryl chloride-induced oxidative cleavage of 133 to generate the 
sulfenyl chloride. In step two, this sulfenyl chloride solution is added to a preformed 
slurry of phthalimide and Hunig’s base to generate the N-thiolated phthalimide 134. With 
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 this transfer reagent in hand, production of the N-(1-phenylethyl)thiolated β-lactam 135 
proceeded smoothly by addition of one equivalent of the N-protio β-lactam 108 and three 
equivalents of triethylamine in a benzene reflux. Adduct 135 was obtained as an 
equimolar mixture of racemic diastereomers.
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Figure (3.18) Successful Synthesis of an N-Thiolated β-Lactam from an Alcohol. 
 With the absence of a free thiol in this synthesis, this appeared to be an effective 
method for generation of the enantiomerically pure sec-butylthio β-lactams. At about this 
time, the R and S sec-butanols became available at a reduced cost and were therefore 
purchased, instead of being independently synthesized. Alcohols in hand, each one was 
chlorinated, thioesterified, and eventually converted to the N-thio lactams via the route 
developed in Figure 3.19 for the R enantiomer (136-140). The process was repeated to 
generate the S enantiomer (141-145). 
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Figure (3.19) Enantiospecific Synthesis of Enantiomerically Pure N-sec-Butylthio β-
Lactams from Optically-pure Alcohols. 
 To prepare enantiomerically and diastereomerically pure lactams for more 
detailed bioassays it was necessary to couple an enantiomerically pure version of lactam 
108 and 139. Fortunately, this proceeded smoothly utilizing the same enzymatic 
resolution scheme described above.[103] To provide a handle for resolution, the C3 
acetylated β-lactam 146 was synthesized via the standard procedures previously 
described, simply starting with acetoxyacetyl chloride instead of methoxyacetyl chloride. 
As developed earlier through a collaboration with Dr. Bisht (University of South Florida), 
Lipase PS-30 efficiently hydrolyzed only one enantiomer 147 from the racemic mixture 
of acetoxy-lactams, leaving the other enantiomer 148 unaffected (with greater than 97% 
ee’s). These two products were then separated via column chromatography. The 
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 hydrolyzed enantiomer, 147, was re-acetylated by acetic anhydride in pyridine to give (+) 
149.[104] 
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Figure (3.20) Successful Synthesis of Enantiomerically Pure β-Lactams. 
With both lactam enantiomers 148 and 149 prepared, what followed was the N-
dearylation with ceric ammonium nitrate to produce enantiomerically pure N-protio β-
lactams 150 and 151, respectively.  
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Figure (3.21) Dearylation of Enantiomeric β-Lactams 150 and 151. 
By applying both R and S sec-butylthio phthalimde transfer reagents 142 and 143 to each 
of these β-lactam enantiomers 50 and 51, four separate stereoisomers were produced 
(152-155). Lactams 152 and 155 are enantiomeric with each other, as are compounds 153 
and 154. These four compounds were tested independently for antibacterial activities. 
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Figure (3.22) Synthesis of Lactams 152-155. 
3.4.1 Oxidation 
 For comparison of the N-sulfenyl lactams just described, more highly oxidized 
sulfur side chain analogues were also needed for biological screening. The structures of 
these compounds are shown below (Figures 3.25 and 3.26). Unfortunately, the 
preparation of these derivatives by thiolation of the N-protio lactam was made difficult by 
the inability to synthesize the necessary N-thio phthalimide transfer reagents, such as 156. 
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Figure (3.23) Attempted Preparation of N-Sulfinyl Phthalimide 
 Oxidation of the phthalimide sulfenamide was successful, but transfer of the sulfinyl 
group to the lactam did not work under the usual conditions (refluxing dichloromethane, 
Hunig’s base and N-protio β-lactam) (Figure 3.24). 
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Figure (3.24) Second Ineffectual Method of Sulfoxyl and Sulfonyl Transfer  
The N-sulfinyl and N-sulfonyl β-lactams were instead prepared from the N-
sulfenyl lactams via oxidation (Figure 3.25). There were two sets of oxidation conditions 
that were successful for this procedure, depending on the organothio substituent. One is 
by mCPBA in ether, and the other is by 30% hydrogen peroxide in acetic acid. In the case 
of the N-cyclohexylthio lactam 109i, only the peroxide method worked to give the N-
sulfinyl product 157b, whereas mCPBA cleaved the sulfur-nitrogen bond. Re-subjection 
of this N-sulfinyl compound to the hydrogen peroxide conditions afforded N-sulfonyl 
product 158b in a nearly quantitative yield. This pathway also worked well for the 
generation of N-phenylsulfinyl 157a and N-phenylsulfonyl 158a β-lactams from the N-
phenylthio β-lactam 109j. In the other case examined, where the sulfur sidechain is the 
sec-butyl in 109g, peroxide was completely ineffectual. Here, mCPBA allowed for the 
conversion of the sulfenamide to the N-sulfinyl lactam 157c; however further oxidation to 
 91
 the sulfonamide 158c with additional mCPBA could not be accomplished. Instead, 
cleavage of the nitrogen-sulfur bond was again observed.  
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Figure (3.25) Oxidative Routes to N-Sulfinyl and N-Sulfonyl Lactams. 
 N-Sulfonic acids and sulfonate salts were formed in a completely different 
manner than above. This turned out to be the only direct method of installing a sulfur 
sidechain on the lactam nitrogen. A sulfur trioxide / pyridine / DMF transfer solution was 
used[105]. This pathway directly provides the potassium N-sulfonate salt which can be 
converted by ion exchange to the tetrabutylammonium salt 159. Eluting the 
tetrabutylammonium salt 159 down a standard silica gel chromatography column gave 
the sulfonic acid derivative 160 in good overall yield. 
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Figure (3.26) Route to N-Sulfonate and N-Sulfonic Acid Lactams. 
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Figure (3.27) Organothiolated β-Lactams Synthesized. 
3.5.1 An N-Resinthiolated β-Lactam 
 For the purpose of trying to identify the intracellular targets of these novel 
antibacterial agents, as to be discussed in chapter 5, a lactam-bound polymer resin 165 
was synthesized. The hypothesis is that an intracellular target could be physically 
captured by the appropriate resin. The first of two methods examined in this study 
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 involved Merrifield’s resin (161) as a solid support on which the lactam could be attached 
through an N-thiolation process. This chloro benzyl material was subjected to thiolation 
via sodium hydrosulfide in water with cetyltriethylammonium bromide. Since this 
commercially available resin, and the expected product, is 2% crosslinked with 
divinylbenzene, it is completely insoluble in the available solvents, thus making NMR 
verification of the product difficult without a solid phase NMR probe. However, a 
standard chemical test for the presence of free thiols, sodium nitroprusside, demonstrated 
the total absence of the expected thiolation product (162). Infrared spectroscopy also 
indicated the absence of the S-H stretch that would be expected around 2500 cm-1 for 
162. Potentially, 162 could dimerize to form a disulfide but no disulfide S-S stretching 
peaks were observed in the expected region around 500 cm-1. 
Cl SHNaSH
161 162  
Figure (3.28) Attempted Direct Thiolation of Merrifield’s Resin 
Fortunately, another, although less direct, method of resin thiolation was 
successful. With the insolubility of this resin, workups at each stage of the synthesis were 
simple and consisted of a set of filtrations with boiling solvent washings. The first step of 
the procedure was to thioesterify Merrifield’s resin (161) with thiolacetic acid and 
triethylamine, a method similar to that previously used for the synthesis of chiral 
thiolated lactams.[102] This provided thioester 163, which was confirmed by a single 
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carbonyl stretch which was apparent in the infrared spectrum. Next, a two-step, one-pot 
procedure converted thioester 163 to the N-thiolated phthalimide transfer reagent 164. 
This analogue was also confirmed by infrared spectroscopy through the appearance of 
two carbonyl stretching peaks representing the phthalimide carbonyls. The first step 
involved the addition of sulfuryl chloride in carbon tetrachloride to the thioester 163 to 
generate the in situ the sulfenyl chloride. This solution was then added to a benzene 
solution of phthalimide and Hunig’s base. Hunig’s base proved to be the highest yielding 
choice of amine bases, over triethylamine and pyridine, for this deprotonation. With the 
synthesis of this N-resinthiolated phthalimide transfer reagent 164 complete, the 
production of the N-resinthiolated β-lactam 165 followed through the standard transfer 
conditions of mixing 164 with N-protio β-lactam 107 in the presence of Hunig’s base. 
The reaction was done in benzene and refluxed for 24 hours. After completion, thorough 
washing of the resulting resin commenced with a myriad of solvents until no solutes were 
detectable by TLC or NMR. However, exposure of the resin to diisobutyl aluminum 
hydride (DIBAL) resulted in the release of a nearly quantitative yield of the N-protio β-
lactam 107, which was observed in the 1H NMR spectrum of the post-reaction washings. 
As well, infrared examination of resin 165 demonstrated only one carbonyl stretching 
indicating the absence of the phthalimide and providing evidence to formation of the 
resin-lactam adduct.  
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Figure (3.29)  Successful Synthesis of an N-Resinthiolated β-Lactam. 
3.6.1 A Fluorescence System 
 Another synthetic target, proposed for experiments to probe the basis for 
biological activity of these lactams, consisted of a Forster Resonance Energy Transfer 
(FRET) quenching pair, to be discussed in further detail in chapter 5. The model system 
involved the placement of N-naphthylthio and C3-dansyl groups onto the β-lactam ring, 
where dansyl is a fluorescence quenching accepter for naphthalene. The first attempt to 
synthesize this compound, 77, involved deacetylation of β-lactam 166 with potassium 
hydroxide in methanol to give alcohol 167, which was then deprotonated with sodium 
hydride and coupled with dansyl chloride. This product, 168, was isolated but could not 
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 be further derivatized to the N-naphthylthiolated β-lactam. Instead, all attempts to install 
this thiol group with phthalimide transfer reagent 169 resulted in lactam ring cleavage. 
Therefore, another route was proposed in which the thiol moiety would be installed first, 
producing lactam 170. The dansyl substituent would then be introduced to produce FRET 
product 171. However, while the naphthylthiol substituent was installed smoothly, the 
addition of dansyl chloride resulted, again, in lactam ring cleavage. Thus, 171 could not 
be prepared via either route shown in Figure 3.30. 
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Figure (3.30) Attempted Synthesis of a Model FRET System. 
Another FRET paired system was then targeted with the fluorescein analogue 172 
and 4-N,N-dimethylaminoazobenzene-4’sulfonyl (dabsyl), donor-acceptor pair. This first 
step of this process involved the esterification of this carboxylic acid and etherification of 
the alcohol with methyl iodide in an acetonitrile slurry of potassium carbonate, which 
proceeded but with a very small yield.  
 97
 OH3CO O
OCH3
O
Cl Cl
173
OHO O
OH
O
Cl Cl
172
MeI, K2CO3
MeOH
 
Figure (3.31) Methylation of Fluorescein. 
From 173, two routes were attempted to yield the free thiol 175. The first route 
was meant to utilize the successful processes of past experiments by first generating the 
thioacetate 174, which would then be saponified to the thiol. However, thioesterification  
of the chloro precursor 173 completely failed. Secondly, a very direct method of 
arylthiolation through the use of sodium hydrosulfide in water, with the phase transfer 
catalyst cetyltriethylammonium bromide (CTAB), was carried out, but did not generate 
product.[106]  Finally, a literature procedure for thiolating aryl halides via sodium 
thiophosphate dodecahydrate directly from 173 delivered about a 50% yield of 176.[107] 
Selectivity was not as high as hoped though, and a mixture of thiolation products 176a 
and 176b from substitution of either of the two chloride groups and 176c, from 
displacement of both chlorides, was obtained. This mixture appeared as one spot by thin 
layer chromatography and was therefore used as a mixture without attempts at separation.  
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Figure (3.32) Thiolation of Fluorescein. 
This mixture was then subjected to the standard procedures of chlorination, 
followed by reaction of the in situ generated sulfenyl chlorides with phthalimide, to give 
N-thio phthalimdes in a about a 40% yield of 177a-c. This mixture was then subjected 
directly to reaction with the N-protio β-lactam 107 in the presence of triethylamine in 
refluxing benzene. Visible in the crude 1H NMR spectrum were two doublets (J = 5.0 Hz) 
for the two β-lactam protons. As well, these doublets were significantly shifted downfield 
from the doublet and triplet positions of the N-protio β-lactam 107. Unfortunately, this 
product could not be purified. The only recoverable lactam following column 
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 chromatography was the starting material, 107. Without the ability to cleanly transfer the 
N-fluoresceinylthio group to the β-lactam, there was no point in pursuing the C3 
dabsylated lactam. 
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Figure (3.33) Fluoresceinylthiolation of the Phthalimide Reagent. 
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Figure (3.34) Fluoresceinylthiolation of the β-Lactam. 
Future work should probe the viability of a coumarin/dinitrophenyl FRET paired 
β-lactam, which may encounter fewer synthetic problems. 
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Figure (3.35) Coumarin / Dinitrophenyl FRET Paired β-Lactam. 
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CHAPTER FOUR 
N-ORGANOTHIOLATED β-LACTAMS: STRUCTURE ACTIVITY 
RELATIONSHIPS 
 
4.1.1 Introduction: Finding Structure Activity Relationships 
 One of the original goals of this project, in essence, was to understand the 
minimum structural requirements of N-thiolated β-lactam antibiotics to sustain 
antimicrobial activity. In this chapter, the testing of compounds prepared in chapter 3, 
and the effects that sulfur side chains have on activity of the lactams is presented.  
4.1.2 Initial Antibacterial Screening 
The initial method for antibacterial screening was executed by the Kirby-Bauer 
disk diffusion method. In this procedure, a cultured bacterium such as Staphylococcus 
aureus was streaked out (inoculated) on an agar filled Petri dish to encourage a 
homogeneous coat of growth across the surface of the plate. Next, 6 mm blank paper 
disks impregnated with 20 µg of the chosen β-lactam analogue (or control agent such as 
penicillin G or Vancomycin) were arranged on the streaked plate, spaced with an 
appropriate distance as to not interfere with each other. These plates were then covered 
and incubated at 37oC for 24 hours. The expected result for antibacterial agents was to 
see what is called a halo effect, or zone of growth inhibition, around the impregnated 
disk. This halo is due to the inhibition of bacterial growth elicited by the antibacterial 
agent. Demonstrated in Figure 4.1 is such an assay comparing the effects of penicillin G, 
(to the left), Vancomycin (at the top), an inactive analogue (to the right) and a very active 
 N-thiolated β-lactam (at the bottom). The larger these halos, or zones of inhibition, the 
more potent the antibacterial activity. In this example, the bacterium was a methicillin-
resistant strain of Staphylococcus aureus, MRSA. It is quite clear from this test that 
vancomycin is more potent than penicillin, but the N-thiolated β-lactams are stronger still. 
 
Figure (4.1) Antibacterial Testing by Kirby-Bauer Disk Diffusion. 
4.2.1 MRSA Activities  
 As mentioned, substitution on the nitrogen center of the β-lactam ring is key to 
activity. Early in this program the importance of a sulfur group directly bonded to 
nitrogen quickly became quite evident. N-Protio and N-para-methoxyphenyl lactams 179 
and 180, as well as others having an N-phenylselenyl, N-chloro, and N-benzyl groups, 
were chosen as a first round of N-substituents (Figure 4.2). These analogues proved (179-
 102
 183) to have no activity against a panel of bacterial species. However, an additional 
sulfenyl analogue, the N-phenylthiolated β-lactam 184, demonstrated potent activity 
against a variety of bacteria. 
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Figure (4.2) Different N-Substituted β-Lactam Analogues Tested. 
 Although activity persisted with variation in the identity of the sulfur sidechain 
from S-alkyl to S-aryl, changes in the oxidation state of the sulfur center was 
extraordinarily detrimental to activity (Figure 4.3). Thus, disulfide 185 and 
methylsulfonyl lactam 186 were devoid of activity. N-Benzylthio and N-methylthio 
lactams, 187 and 188, were about equally as potent. These early studies led us to believe 
that any increase in the oxidation state of the sulfur substituents on these N-thiolated β-
 103
 lactams completely obliterates antibacterial activity. However, later results with different 
types of sulfur-substituted derivatives showed that some S-oxidized forms are tolerated.  
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Figure (4.3) Initial Variations in the Sulfur Sidechain Oxidation State. 
 To further evaluate the influence of the N-thio moiety on antibacterial activity an 
SAR study of alkyl-thiolated β-lactams was conducted, the synthesis of which is 
described in chapter 3. The N-methythio β-lactam 109a was shown to be a potent 
inhibitor of MRSA strains, with an average zone of inhibition of about 28 mm (Table 
4.1). Comparatively, penicillin G demonstrates a zone of less than 15 mm against the 
same strains. And Vancomycin (94), the most potent clinical antibiotic for MRSA, only 
ranks a zone of about 18 mm. The next step was to extend the chain of methylthio 
compound 109a by one methylene unit to the N-ethylthio β-lactam 109b. This change 
raised the anti-MRSA activity to 31 mm. Further elongation of the straight chain, 
however, only demonstrated a steady decline in zone of inhibition sizes. As can be seen 
in Table 4.1, S-propyl- 109c, S-butyl- 109d, and S-octyl- 109e moieties had diminished 
activities compared to that of the N-ethylthiolated β-lactam 109b.  
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 Table 4.1  
N-Alkylthiolated β–Lactams Vs Standard Antibiotics
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Examining these bioactivity trends, the notion may arise that this diminishing 
effect on antibacterial activity as a function of S-alkyl chain length may simply be 
proportional to the analogues ability (or inability) to diffuse across the agar surface. 
Increasing S-alkyl chain length could certainly inhibit migration from the disk, leading to 
decreasing zone sizes as an artifact of the experiment.  
This exact problem arose upon the search for an SAR between different alkyl 
chain lengths at C3.[87] In that case longer chain lengths also show decreased antibacterial 
activities via Kirby-Bauer screening. However, upon further investigation by methods 
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 which are independent of diffusability requirements, the trend in bioactivities was 
actually shown to be reversed to that of Kirby-Bauer testing. In other words, the longer 
C3 sidechain analogues were actually more active than their shorter chain counterparts, 
and the trend in diminishing activities as measured by zone of inhibition testing was 
indeed an artifact of the method (Figure 4.4).  
 
Figure (4.4) Relationship of C3 Side Length to Antibacterial Activities.[87]
The first step taken to determine if a similar scenario is being created with the 
sulfur sidechain was to repeat the Kirby-Bauer disk diffusion experiments by a similar 
method, well diffusion. This methodology involves burrowing a 6 mm cylindrical well 
into the agar after streaking out the bacteria, and adding 20µl of a 1µg/µl solution of the 
analogues into the wells. The plates were then incubated as usual for 24 hours. The 
reason for doing the agar diffusion assays this way was to see if there was a problem of 
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the lactams not being able to diffuse off of the cellulose disk. By adding the lactam 
solution to the wells, there could be no interference due to physical adsorption onto the 
surface of the disks. These results, however, were essentially the same. Overall, the zone 
of inhibition values were slightly larger than with disk diffusion, but the relative trends in 
bioactivity were unchanged.  
Believing that the sudden drop in activity for the long chain lactam analogues 
could still be an artifact of agar plate testing, a different type of experiment was 
performed to measure minimum inhibitory concentration, or MIC, values in broth media. 
MIC determination is an accepted means for assessing antimicrobial activity of 
compounds. This method is an aqueous phase technique, where bacteria, nutrients (like 
agar, called Mueller-Hinton broth), and antibiotic candidates are all suspended in solution 
together. The minimum amount of compound required to completely inhibit visible 
bacterial growth (100% growth inhibition) is the MIC value for that compound. The 
lower the MIC is, the stronger is the drug’s bioactivity. This method is without concerns 
of diffusion since the drug is dispersed homogeneously throughout the experimental 
vessel. Bacterial growth is examined optically for changes in opacity due to increasing 
cell counts, and is considered to be very accurate (done in triplicate). Indeed, these 
experiments further substantiated that the increase in sulfur chain length leads to a steady 
increase in MIC values, and thus to a drop in bioactivity. For example, the N-ethylthio β-
lactam 109b has an MIC value against MRSA of only 8 µg/ml, while N-octylthio β-
lactam 109e has an MIC of 64 µg/ml (Table 4.2). So, a shorter sulfur sidechain must 
either react better with the cellular target or positively influence delivery to the target. 
 The differences in reactivity between analogues of different bioactivity are explored more 
deeply in chapter 5.  
Along with the MIC testing, it is quite convenient to do another test to determine 
the minimum bactericidal concentration (MBC). MBC screening quickly determines if a 
compound is bacteriostatic or bactericidal. Classical β-lactam antibiotics are bactericidal, 
however, of the N-thiolated β-lactams which were tested for an MBC all were shown to 
be bacteriostatic. Each MIC sample that displayed 100% inhibition of bacterial growth 
was streaked out onto an agar plate, allowed to incubate for an additional 24 hours, and 
yet displayed a positive growth of bacteria. This MBC evidence again points to a mode of 
action for these compounds differing from that of penicillin. 
Table 4.2 
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Of course, linear alkyl chains are not the only possibility for the sulfur 
substituents. Investigating the effects of branching with these chains, or aromaticity, 
should provide some evidence for, or against, a steric effect on bioactivity. The first study 
involves a simple variation of the ethylthio substituent with a longer, branched N-
isopropyl group 109f. This change in structure led to an increase in the anti-MRSA 
activity, from 31 mm for ethyl to 33 mm (Table 4.3). Steric hindrance around sulfur 
seems to be ineffectual, or to even enhance growth inhibition. Further lengthening of the 
alkyl chain, to sec-butyl 109g, further increased potency to 40 mm. This is greater than 
twice the zone size of the same quantity (20 µg) of vancomycin (94)! MIC testing 
concurred with the potency of this compound, yielding a value of less than 0.5 µg/ml for 
100% growth inhibition (Figure 4.5).   
A alternative way to compare the relative potencies of the N-sec-butylthiol 
analogue 109g to that of other compouns is by Kirby-Bauer testing against MRSA, as 
shown in Fig. 4.5. This plate contains four disks loaded with different test compounds. To 
the right of the plate is a disk containing 20 µg of an inactive compound To the left is a 
disk impregnated with 20 µg of penicillin G (78), which produces a very small zone of 
inhibition. At the top of the plate is another disk impregnated with 20 µg of vancomycin 
(94), a non-β-lactam antibiotic considered the last line of defense against MRSA. Lastly, 
at the bottom of the plate is a disk containing N-sec-butylthio β-lactam 109g. The 
differences in bioactivities are clearly visible. 
  
Figure (4.5) Comparison of N-sec-Butylthio β-Lactam 109g to Clinical Standards. 
The next step was to further hinder the sulfur center of these lactams by 
synthesizing and testing the N-tert-butylthio analogue 109h. The synthesis of this 
compound was described in chapter 3, and turned out to be a difficult task. Fortunately, a 
small amount was synthesized for testing. Surprisingly, this exchange of N-sec-butyl to 
N-tert-butyl nearly obliterated anti-MRSA activity, with a zone size being reduced down 
to 10 mm. The reason for this appreciable drop in bioactivity in going from N-sec-
butylthio to N-tert-butylthio is not entirely clear. Sterically, this change certainly creates 
greater bulk directly around the sulfur center, but electronically there is also a greater 
induction of electrons into to the sulfur atom. Both factors may decrease electrophilicity 
toward cellular thiophiles. However, if steric bulk alone was influencing the lability of 
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 the N-S bond, then one must wonder why the thiol transfer process occurred from 
phthalimide to lactam occurred so readily.  
Another series of N-thiolated lactams to examine was that of cyclic and aromatic 
systems. To this end, N-cyclohexyl, N-phenyl and N-benzyl β-lactams 109i-k, 
synthesized as shown in chapter 3, proved valuable. Table 4.3 compares the bioactivity of 
these three compounds to the branched lactams 109f-h. All three of the cyclic variants 
showed lower activity that the sec-butyl and isopropyl analogues, and were roughly equal 
to each other in activity. Thus, the presence of cyclic side chains on sulfur diminished 
anti-MRSA activity to some degree. 
Table 4.3.  
 
Gray bars = MSSA, Black bars = MRSA strains 
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 Attempts to synthesize more complicated branched sidechain derivatives for 
further studies were unsuccessful, all examples of which are shown in Figure 3.29. In 
these cases, even the phthalimide transfer reagents were difficult to synthesize. This, of 
course, is likely due to major steric hindrances afforded by bulky constituents.  
The next objective was to study some N-thiolated lactams bearing heteroatom-
containing side chains on sulfur. A series of these were attempted without success as 
shown in Figure 3.27. Attempts to prepare these compounds failed. In most cases the 
synthesis of the requisite phthalimide transfer reagent occurred without any problems, 
such as the case of a N-p-methoxyphenylthio analogue. However, transfer of the thio 
moiety onto the lactam never occurred in a useful yield after purification. Other methods 
of N-thiolation also failed. Direct N-thiolation with a sulfenyl chloride always resulted in 
either recovery of the starting N-protio lactam 107 or in cleavage of the lactam ring as 
shown in Figure 3.9. Installing the thiol groups onto the imine prior to the Staudinger 
cyclization, as suggested in the literature[101], also proved ineffective for the synthesis of 
these compounds (Figure 4.6).  
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Figure (4.6) Attempt to Prepare N-Tritylthio Lactams from N-Tritylthioimines. 
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Next, compounds having additional heteroatoms (oxygen) directly on the sulfur 
center were examined. As shown in Figure 4.3, initial results demonstrated no activity for 
lactams bearing a sulfur at a greater oxidation state than the sulfenyl systems discussed 
thus far. Further investigation with some additional analogues, however, seemed 
warranted. Thus, the synthesis of N-cyclohexyl lactams 109i, 157b, and 158b and N-
sulfonic acid analogue 160 described in Chapter 3 enabled a comparison of their 
bioactivities. For these four compounds, the N-sulfenyl and N-sulfinyl lactams exhibited 
similar bioactivities, while the N-sulfonyl lactam was appreciably less active, and the N-
sulfonic acid was devoid of bioactivity. This differs from the previous observations that 
S-oxidation destroys activity. Logically, the most active analogue, N-sec-butylthiol β-
lactam 109g, should be the analogue to oxidize and test comparatively for antibacterial 
effects. However, oxidation of 109g with hydrogen peroxide (Chapter 3) led to cleavage 
of the nitrogen-sulfur bond. Fortunately though, oxidation of 109g to N-sec-butylsulfinyl 
157c analogue could be achieved with slightly less than one equivalent of meta-
chloroperoxybenzoic acid (mCPBA). Further oxidation with another equivalent of 
mCPBA did not facilitate the synthesis N-sec-butylsulfonyl analogue however. Instead, 
the lactam ring was deannulated and the same results occurred with the use of other 
oxidants under a variety of conditions. Unlike N-cyclohexylsulfinyl analogue 157b, this 
N-sec-butylsulfinyl compound 157c retained only weak antibiotic activity as evidenced 
by a zone size ~ 25 percent the diameter of that produced by the N-sulfenyl lactam. 
 
 
 Table 4.4  
 
Black bars = MRSA strains, Gray bars = susceptible S. aureus 
 
 Thus far, all of the β-lactam antibacterial activities discussed have been prepared 
and tested as racemic mixtures. The bioactivity of many drugs depend heavily on 
stereochemistry. So, it seemed very important to examine these chiral N-thiolated β-
lactams more closely with respect to their relative and absolute stereochemistry. Even 
though no cytotoxic effects have been demonstrated for these antibiotics[113], perhaps one 
or more analogues might be more potent than the others. 
 To examine these possible stereochemical effects the N-sec-butylthio β-lactam 
109g was chosen as the test candidate for its three chiral centers, and potency. 
Unremarkably, there was very little difference between each of the four stereoisomers 
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 152-155.  However, what is curious and potentially meaningful is that cis “up” 
stereoisomers 152-153 have equal potencies, which are greater than that of their β-lactam 
enantiomers cis “down” stereoisomers 154-155. Also of note is that variations in β-
lactam ring stereochemistry have no effect on bioactivity when the N-organothio 
substituent is not chiral, such as N-methylthio.[100]
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Figure (4.7) Dependency of Anti-MRSA Activity on Lactam Stereochemistry. 
 
 So it seems that the overall configuration of N-thiolated β-lactams is important to 
bioactivity, perhaps for delivery to a target or to avoid aggregation of the drug, but 
stereochemistry of the most important substituent, the N-organothio group, is 
unimportant.  
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 4.3.1 Anthrax 
In addition to Staphylococcus species, the N-thiolated β-lactams have potent 
antibacterial effects on Bacillus species. Initial experiments with Bacillus anthracis 
showed that the same SAR as that for MRSA seems to hold up for B. anthracis. The 
analogues with the most potent activities against MRSA, such as N-sec-butylthio β-
lactam 109g, are still these most potent against B. anthracis. So, it seems very likely that 
whatever is causing activity of the lactams against MRSA is the same for B. anthracis. 
This will be further explored and discussed in chapter 5. 
Preliminary studies of N-Alkylthiolated β–Lactams vs
Anthrax
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Figure (4.8) Kirby-Bauer Screening of N-Thiolated β-Lactams Against Anthrax. 
 
 Table 4.5 shows a sampling of structures and respective activities of N-thiolated 
β-lactams against Bacillus anthracis, the causative agent of anthrax. The standard clinical 
antibiotic of choice to treat anthrax infections, Ciprofloxacin, has a zone of inhibition of 
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 40 mm by agar disk diffusion. This is slightly less than that of the sec-butyl analogue 
109g.  
Table 4.5 
N-Alkylthiolated β–Lactams vs Anthrax
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Ciprofloxacin, the current drug of choice to treat Bacillus anthracis, demonstrates a  
zone of inhibition of 40mm. 
 
 
 Anthrax was not the only Bacillus species tested, however. B. cereus, B. 
coagulans, B. globigii, B. megaterium, B. subtilis, and B. thuringenesis were also 
inhibited by N-sec-butylthiol β-lactam 109g, with zones of comparable size to those 
produced by Ciprofloxacin (Table 4.6). As well, the same trends seen for anthracis hold 
true for the remainder of these six species of Bacilli. These shared trends seem to point to 
a common mode of antibacterial action of the N-thiolated β-lactams in Staphylococcus 
and Bacillus, which will be explored further in chapter 5. 
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CHAPTER FIVE 
N-ORGANOTHIOLATED β-LACTAMS: MODE OF ACTION AND AN 
INTRACELLULAR TARGET 
 
5.1.1 Introduction 
 
 As discussed in chapters 1 and 2, classical β-lactam antibiotics inhibit bacterial 
growth by interrupting cell wall crosslinking. Studies completed in this lab have shown 
that cell wall crosslinking inhibition is not the mode of action of N-thiolated β-lactams.[18] 
Evidence to this fact includes no changes in cellular morphologies, via examination by 
scanning electron microscopy of cells treated with N-thiolated β-lactams, and no change 
in cell wall density as determined by Gram-staining. Drastic alterations in morphology 
and cell wall thickness occur for the same cells treated with penicillins. This means that 
for the first time a β-lactam antibiotic has a mode of action not directly related to cell 
wall synthesis. The purpose of the work discussed in this chapter was to find out where in 
the cell these drugs are going, what are they interacting with and how do these 
interactions produce inhibitive effects. 
5.2.1 Chemical Interaction 
 Since it seems apparent from the SAR studies that the sulfur sidechain of these N-
thiolated β-lactams is paramount to antibacterial activity, and that other evidence from 
our laboratories suggests that these lactams are impervious to radicals, there are really 
only three logical reaction mechanisms to consider in terms of the compounds biological 
mode of action. The first pathway is that some bio-nucleophile attacks the carbonyl 
carbon, C2 of the lactam, thus opening the ring (Figure 5.1). This pathway is identical to 
 the fate of all other β-lactam antibiotics whose mode of action involves attack at that very 
same site by a serine residue of the transpeptidase enzyme. However, logic would dictate 
that if this was the site of attack, stronger electron-withdrawing groups on the lactam 
nitrogen would be expected to increase the electrophilicity, and thus reactivity, of the 
lactam ring. Thus, although increased reactivity does not always mean increased activity 
an N-sulfonyl lactam should be more active than an N-sulfinyl, which should, in turn, be 
more active than the N-sulfenyl derivatives. In actuality though, the precise reverse trend 
in bioactivities is seen. If this was not enough to rule out this pathway, it is important to 
point out that the N-protio β-lactam can be isolated un-cleaved after treatment with 
bacterial culture media. 
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Reverse is observed SR > SOR > SO2R >SO3H  
Figure (5.1) Nucleophilic Attack at C2 . 
 The second potential site of attack on the lactam by a biological nucleophile is the 
first carbon of the sulfur sidechain (Figure 5.2). If this site was the point of nucleophilic 
attack, then it would be expected that less hindered groups like methyl, as compared to 
ethyl or even isopropyl, on sulfur would be the most reactive. However, the exact reverse 
trend in bioactivity is seen. The isopropyl-substituted system was one of the most active 
analogues, certainly more active than the ethyl and methyl analogues. 
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Figure (5.2) Nucleophilic Attack at the Alpha-carbon of Sulfur Sidechain. 
 The third, and final, site of attack to consider is the sulfur center itself (Figure 
5.3), which seems very likely. First of all, the sulfur atom has proven to be absolutely 
required for antibacterial activity of these compounds and therefore attack at that site is 
possible. Secondly, attack at the sulfur center, and thus ejection of the lactam ring intact, 
fits well with the finding that the intact N-protio lactam is recovered cleanly from culture 
media. Shorter sulfur sidechains mean lower lipophilicity and therefore a better chance 
for the lactam molecule to pass completely through the cellular membrane into the 
cytoplasm to interact with some intracellular constituent. 
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Figure (5.3) Nucleophilic Attack at Sulfur. 
 Also shown previously in this lab and in others (Shah/ Cama), is the extreme 
reactivity of these N-thiolated β-lactams toward free thiols, such as 2-mercaptopyridine 
(Figure 5.4).[99] This shows a selectivity of thiophilic nucleophiles for this electrophilic 
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 site, and points to the likelihood of attack here by some intracellular thiol nucleophile. N-
Thiolated β-lactams are otherwise quite stable towards radicals, acidic conditions, and 
weakly basic conditions. 
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Figure (5.4) Chemical Reactivity of N-Thiolated β-Lactams to Thiophilic Reagents. 
 So the questions that remain are: where does the biological action occur, what is 
the intracellular target, and how does this interaction confer antibacterial activity? 
Attempts to answer these questions are what follows in this chapter.  
5.3.1 Loci 
 The first experiments done in this lab by Dr. Timothy Long to determine where 
these drugs may end up in a bacterial cell involved radiolabeling.[108] For the lowest cost 
and smallest number of “hot” synthetic steps, the N-methylthio β-lactam was synthesized 
with all three methyl hydrogens swapped for tritium labels. Unfortunately, the results 
from this experiment did not show where the drug went, only where it did not go. These 
lactams were not detected in any appreciable levels in cellular fractions contatining DNA, 
RNA, or proteins. At the time, low molecular weight targets were not considered and 
quite possibly the radio-tag was thrown out with the cellular bath water. Experiments 
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were underway, at the time of this dissertation’s completion, to use radiolabeling to 
detect small molecule targets in aqueous fractions. 
 A different method to follow the drug’s pathway into the cell was considered to 
measure fluorescence uptake. The first idea was to attach a fluorophore as part of the 
sulfur sidechain, to trace the path of this fluorophore through the bacterial cell membrane 
and into the cell. To see precisely the location within the cell where the lactam may 
interact with its target, a Forster Resonance Energy Transfer (FRET) pair was built into 
the N-thiolated β-lactam framework. The principle with FRET is that two functional 
moieties are installed in the framework where the fluorescence wavelength of one, the 
donor, would overlap with the absorption wavelength of the other, the acceptor. In this 
way the fluorescence of the donor would be quenched by the acceptor. Also of note is 
that this FRET phenomenon is greatly distance-dependent. Therefore, as the donor and 
acceptor are separated, the quenching effect exponentially decreases and the donor “lights 
up” as its fluorescence is released. If a donor, like a naphthyl group, is incorporated in the 
sulfur sidechain and the acceptor is attached to the lactam moiety, like a dansyl group, 
perhaps at C3 or C4, then once the sulfur-nitrogen bond is cleaved fluorescence would be 
emitted (Figure 5.5) as it moved away from the lactam. So the model system was a 
napthyl-dansyl FRET pair 171. 
 Probing the Mechanism of Action via 
Forster Resonance Energy Transfer
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Figure (5.5) FRET Pair Concept. 
 
 In practice, however, there were significant problems. Unforeseen synthetic 
challenges thwarted efforts to synthesize this FRET pair 171 impossible. Even after 
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changing the order of steps for introducing the two fluorescent side chains, lactam ring 
decomposition still occurred, preventing formation achievement of the final FRET 
product. As well, this was only, at best, a model system, as the donor fluorophore 
(naphthyl) is simply not red-shifted enough to be of use for cell structures. Naphthalene’s 
fluorescence wavelength is fairly blue ( λemission = 380 nm), as is the auto-fluorescence of 
bacteria. So, the small, faint blue light of this fluorophore would be difficult to observe 
amongst the large intense blue background of the cell. The compound and the 
background could, theoretically, be differentiated based on fluorescence lifetimes, but no 
real-time imaging would be possible. 
 Thus, another FRET candidate, with the appropriate fluorescence wavelength, 
was selected for synthesis, a fluoresceinyl / dabsyl paired compound 178. However, 
initial attempts tp prepare this compound were also unsuccessful for reasons noted above 
for 178. In the future, it may be possible to overcome the difficulties of the synthesis, and 
perhaps use a similar procedure to make coumarin / dinitrophenyl FRET paired 
analogues.  
5.4.1 Sugar Uptake 
 Another sulfenamide, 1,2-benzoisothiazolin-3-one (BIT) (46), has shown weak 
activity against Staphylococcus aureus, with an MIC around 100 µg/ml[57], as discussed 
in Chapter 1. It has been suggested to interact with thiols of biological importance as part 
of its mode of action, such as glutthione. Particularly, however, the molecule has been 
shown to inhibit the glucose uptake pathway of staph. This pathway, called the 
phosphoenol pyruvate phosphotransferase system is responsible for the uptake and 
 phosphorylation of sugars, such as glucose, for metabolism. Inhibition of this pathway 
starves the cell from nutrient absorption. Importantly, the important phosphotransferase is 
highly thiophilic and sharply inhibited by free thiols. Indeed, 46 is known to form an 
adduct with this enzyme an inhibit the glucose uptake of Staphylococcus aureus by 96%. 
It is thus evident that this molecule ring opens across the nitrogen-sulfur bond to reveal a 
free thiol for bioactivity. Since N-thiolated β-lactams have been shown to interact with 
thiols there was reasonable suspicion that they may interact with this sugar uptake system 
in a similar pattern. 
 Using a fluorescence based monitoring kit, glucose uptake of Staphylococcus 
aureus cultures were monitor with and without the presence of N-sec-butylthio β-lactam 
109g, as well as a series of positive an negative controls. As seen in Table 5.1, N-
thiolated β-lactams do not appear to inhibit this pathway, in light of the marginal decrease 
in sugar uptake. Apparently, these drugs are effecting a different system. 
Table 5.1 
 
5.5.1 Identity of the Intracellular Target 
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 Since radiolabeling and fluorescence tagging methods has thus far failed to 
produce insightful data on the N-thiolated β-lactam’s mode of action, another novel 
method of for identifying the intracellular target(s) was investigated. In this experiment 
the goal was to synthesize a polymer resin onto which is covalently bonded an N-
thiolated β-lactam through the sulfur moiety. In this way, it may be possible to use this 
lactam-conjugated resin to capture the cellular target. The plan was to expose the contents 
of bacterial cells to the lactam-conjugated resin, and upon reaction of the cellular target 
with the N-thio moiety, the nucleophile would then be covalently bonded to the resin as 
glutathione is shown to do in Figure 5.6. Once the nucleophile is bonded to the resin, all 
impurities could be washed away. The nucleophile, or intracellular target, could then be 
chemically cleaved from the resin, further purified if necessary, and characterized.  
This indeed proved to be possible. As described in chapter 3, the synthesis of N-
thiolated lactam resin 165 proceeded smoothly to generate a crosslinked N-
polystyrenylthio β-lactam resin (Figure 5.6). To test this resin’s abilities to capture 
thiophilic nucleophiles, it was first subjected to glutathione 9, a common intracellular 
thiol, under pseudo-physiological conditions. The washings of this resin were examine by 
HPLC and 1H NMR for organic compounds, and the N-protio β-lactam 108 was thus 
observed. This experiment successfully produced a resin-glutathione adduct 192 which 
could be chemically cleaved by a number of conditions, like triphenyl phosphine / water, 
or DIBAL / ether, 1H NMR confirmed the recovery of the glutathione 9 after cleavage 
from the resin.  
 S
N
O
O CH3
Cl
S
O
HN
HO
O
S
HN
NH2
OH
OO
Glutathione
PPh3 / H2O
O
HN
HO
O
HS
HN
NH2
OH
OO
+ N
O
O CH3
Cl
H
165
108192
9  
Figure (5.6) Testing of the Lactam-thiolated Resin. 
The resin was also tested in an aqueous solution containing equimolar amounts of 18 
different amino acids including glutathione 9 and cysteine, all at 2 millimolar 
concentrations, with this DMSO swelled resin. After thorough washings, this adduct was 
then cleaved with DIBAL in ether to afford glutathione 9 only. 
Table 5.2 
Amino Acids Stirred with N-Thiolated Resin 
L-cysteine glutathione L-lysine 
L-isoleucine L-methionine L-tyrosine 
L-asparagine L-glutamine L-proline 
L-histidine L-threonine L-tryptophan 
D-threonine L-valine L-alanine 
L-serine DL-phenylalanine 
DL-β-3,4-dihydroxyphenylalanine 
 
 The real goal of these experiments was, of course, to see if the resin could extract 
targets from the intracellular contents of cells. This was completed by first cultivating a 
large number of Staphylococcus aureus cells, then concentrated them from their growth 
media before washing and lysing them via sonication. After centrifugation, the lysate was 
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 filtered to obtain only the soluble contents of the cells. These lysates were then shaken 
with a significant portion of the resin for 24 hours at 37oC. The resin was then thoroughly 
washed and chemically cleaved with DIBAL to obtain the putative target species. One 
and only one compound was captured by this method, Coenzyme A (CoA) (12). 
A simple high pressure liquid chromatography (HPLC) experiment (traces shown 
as spectra 8.51-8.59 on pages 213-221) was performed to demonstrate the formation of 
an organothio-coenzyme A adduct 193. This was quite simple, once the proper eluent 
was discovered. There was an immediate generation of two new, less polar peaks which 
were representative of the adduct 193 and the resultant N-protio β-lactam.  
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Figure (5.7) Thiol-CoA Adduct 193 
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These experiments supported the claim that exposure of the S. aureus lysate to the 
N-thiolated β-lactam would generate the same type of disulfide adduct. This was also 
proven to be so. A relationship between the rate of adduct formation and the antibacterial 
potency of various N-thiolated β-lactams was explored. However, either there is no 
relationship between these properties, or the rate of thiol reaction between coenzyme A 
and the lactam is very fast.  Different N-organothio β-lactams, ethyl, phenyl and sec-
butyl, were separately combined with coenzyme A all at 10 µM in a solution of aqueous, 
pH 7 phosphate buffer and DMSO, and immediately injected into the HPLC. For each 
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sample, it appears that the adducts is formed instantaneously under these experimental 
conditions, with no observable differences in the reactivity of the different N-thiolated 
lactams with coenzyme A. Several questions thus remain. Do different N-thiolated β-
lactams react more readily with the target? Is coenzyme A the only target? Does the 
organosulfur substituent server to enhance activity of the lactam by promoting its 
stability, reactivity, or delivery? Are the disulfide adducts formed between the lactam and 
different thiols stable to reductases? Do the lactams of different bioactivities have 
different stabilities to non-target thiophiles?  
5.6.1 CoA-Antibacterial Effects 
To counteract the effects of oxidative stress, cells have developed an important 
defense mechanism: a thiol / disulfide redox buffer consisting of small molecules and 
proteins with redox-active thiol moieties, disulfides and disulfide reductases (also called 
thiol-disulfide oxidoreductases). Through redox regulation of different target proteins and 
small molecules, disulfide reductases control diverse cellular functions including 
apoptosis, cell proliferation, protein folding, oxidative stress and signal transduction, by 
constantly keeping a fresh supply of free thiols. These antioxidants are particularly 
susceptible to attack by foreign thiophilic agents. At stasis, the reductases keep the 
equilibrium between thiol and disulfide at over 90% thiol. The most well known of these 
is the glutathione / glutathione reductase system. Classically, glutathione was thought to 
be the ubiquitous thiol involved in the thiol / disulfide redox metabolism of all life and 
thus was the thiol of choice for the model experiments with the N-resinthiolated β-lactam 
experiments.  
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So, how does this tie in with Coenzyme A (9)? CoA is a fairly ubiquitous 
chaperone enzyme used, by definition, to assist in enzymatic processes such as re-
naturing and folding. CoA’s role in Staphylococcus aureus, however, has recently been 
found to be much more profound.[109] The exciting part of this discovery is that S. aureus 
has been found to neither produce nor utilize glutathione. Instead, S. aureus utilizes CoA, 
which it generates in millimolar quantities, and coenzyme A reductase (CoADR) as its 
primary thiol / disulfide redox metabolism. Therefore, S. aureus is highly dependant on 
this system to prevent oxidation of important cellular systems, and any disruption, say by 
N-thiolated β-lactams, of this metabolism could result in significant detrimental effects 
for this bacterium.  
Of equal significance, it is important to realize that CoADR is extraordinarily 
selective for CoA-CoA disulfides.[110] It has been shown that CoADR is incapable of 
reducing a mixed disulfide between CoA and glutathione. It is therefore likely that 
CoADR is incapable at reducing a mixed disulfide formed between CoA and the 
organothiolate procured from an N-thiolated β-lactam. In this way, N-thiolated β-lactams 
can possibly inhibit this redox cycle and, eventually downstream, inhibit cell growth. It is 
also possible that the enzyme, CoADR, itself forms an adduct with the thiol from these 
lactams and is thereby irreversibly deactivated. Since the enzyme only bears one thiol, on 
a cysteine residue (Cys43), which is needed for enzymatic activity[110], blockage of this 
site could quickly shut down the entire redox metabolism.   
There is additional evidence to support this mode of action. The bacteria that are 
affected by N-thiolated β-lactams, such as multiple species of Staphylococcus and 
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Bacillus, each use CoA for their primary redox metabolism. Bacteria which are resistant 
to N-thiolated β-lactams, such as Mycobacterium spp., Streptococcus spp., Enterococcus 
spp., and Escherichia coli, are know to utilize other thiols like mycothiol or glutathione 
for their redox cycling. The reductases for these systems are not as selective for their 
homo-disulfide and therefore may simply reduce any mixed disulfides that are formed. 
Human cells also use glutathione and this may be why, amongst other reasons, these 
compounds are non-cytotoxic to healthy tissue. 
 These lactams indeed react well with other thiols such as glutathione. This was 
shown in the case of the lactam-bound solid phase. As well, thin layer chromatography 
experiments show immediate formation of the N-protio β-lactam, when any 
organothiolated β-lactam is mixed in solution with the free glutathione thiol at µM 
concentrations, roughly equal to that known to be present in cytoplasmic fluid. 
Regardless of the identity of the organothio-substituent, the reaction is instantaneous. So 
it seems that the trends in biological activity can be based on neither the reactivity of the 
thiolate with the target, CoA, or the ability to not react with other antioxidants such as 
glutathione. 
 Given glutathione’s reactivity toward different N-thiolated β-lactams seems to be 
the equivalent, the question arises as to what effect glutathione levels in a cell correspond 
to sensitivity of those cells to N-thiolated lactams. Glutathione demonstrates a greater 
ability to inhibit the potency of less active N-thiolated analogues as shown in Figure 5.7. 
As can be seen, three lactams were exposed to zone of inhibition testing, which resulted 
in the less active analogues, 109a and 109b, having greatly diminished zones, while a 
 more active analogue, like 109g, was less affected. So although, all tested N-thiolated 
analogues have a very high rate of reaction with free thiols, like glutathione, biological 
interaction is not a question of rate. Certain structural difference, the same ones that make 
an N-thiolated β-lactam more bioactive, bestow a level of defense against free media 
thiols such as the glutathione distributed in these experiments. 
 
A                                                           B 
Picture A) Each well (small dark circles) was filled with 20 µg of the shown drugs plus 20 µg of glutathione.  
Picture B) Each well was filled with 20 µg of the shown drugs plus 50 µg of glutathione. 
In both cases, incubation was for 24 hours. 
 
Figure (5.8) Effect of Glutathione on Growth Inhibition by N-Thiolated β-Lactams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 133
  134
 
 
 
CHAPTER SIX 
BEYOND BACTERIA: OTHER BIOLOGICAL ACTIVITIES AND 
CONCLUSIONS 
 
6.1.1 Fungi 
As mentioned in chapter 1, fungi, which are eukaryotes, comprise a separate 
group of microorganisms, having a membrane bound nucleus, a more extensive 
endoplasmic reticulum and mitochondria. Compared to bacteria, fungi have a mostly 
chitin-based cell wall, instead of a peptidoglycan like that in Gram-positive bacteria. This 
is why fungi are completely unaffected by traditional β-lactam drugs like penicillin and 
other peptidoglycan cell wall crosslinking inhibitors like Vancomycin. As well, fungal 
DNA is found isolated within the nucleus instead of dispersed throughout the cytoplasm 
as in bacteria. Fungal infections are usually constrained to only the dermis or mucosal 
membranes (superficial mycosis). However, just as resistant bacterial infections, like 
MRSA, are becoming a problem with the increasing prevalence of immune deficiency 
diseases like HIV-AIDS, development of treatments for internal and systemic fungal 
infections (deep mycosis) are of great importance. 
 As discussed in chapter 5, N-thiolated β-lactams have a completely different mode 
of action from that of traditional β-lactam antibiotics, which likely involves the inhibition 
of a cellular redox metabolism. Fungi, are also known to rely on thiol / disulfide redox 
metabolisms to defend themselves from over-oxidation and therefore are potentially 
susceptible to drugs that inhibit these systems. 
  To determine if these N-thiolated β-lactams can serve as antifungal agents, Dr. 
Timothy Long and Marci Culbreath tested N-methylthio lactam 109a against a panel of 
eight different species of Candida, including C. albicans, C. tropicalis, C. glabrata, C. 
kefyr, C. krusei, C. lusitaniae, C. parapsilosis and C. utilis.[111] The antifungal screening 
method closely mimicked the Kirby-Bauer method used for antibacterial screenings. 
Compared to a standard clinical antifungal agent, Clotrimazole, the N-thiolated β-
lactams, specifically 109a, faired quite well. For some species Clotrimazole was more 
potent, but in others the N-thiolated β-lactam was more potent (Fig. (6.1)). 
Table 6.1 
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 This is certainly a departure from standard β-lactam antibiotics. To verify this 
data MIC testing was also performed (Table 6.2). MIC values obtained after 24 hours 
were in the 10 to 15 µg/ml range, with some even lower. 
Table 6.2 MIC’s of Lactam 109a Against Candida Species. 
 
Candida sp. MIC 24 hrs. MIC 48 hrs. 
C. albicans <5 µg/ml <5 µg/ml 
C. tropicalis 10-15 µg/ml 30-35 µg/ml 
C. glabrata 10-15 µg/ml 10-15 µg/ml 
C. kefyr 10-15 µg/ml 35-40 µg/ml 
C. lusitaniae 10-15 µg/ml 15-20 µg/ml 
C. parapsilosis <5 µg/ml <5 µg/ml 
C. utilis 10-15 µg/ml 15-20 µg/ml 
 
This verifies, yet again, that the mode of action of these N-thiolated β-lactams is 
completely novel. The identities of the thiol / disulfide redox metabolisms of these fungi 
have thus far been assumed to be glutathione based. In light of these results, it would be 
very interesting to conclusively determine the true redox metabolism of those fungi 
which are inhibited by N-thiolated β-lactams versus those fungi which are not. If there is 
a strong line of difference between inhibited fungi thiols and uninhibited fungi thiols, a 
potentially important avenue to the design of new antifungal agents would be identified. 
6.2.1 Neoplasmic Systems 
As remarkable as it is that these N-thiolated β-lactam antibiotics are antifungal 
agents, it is perhaps even more intriguing that they are also anti-cancer agents.[111] This is 
the first time that a β-lactam antibiotic has been shown to possess any anti-cancer 
properties. In leukemic Jurkat T-cells, N-thiolated β-lactams have demonstrated the 
ability to induce DNA damage and inhibit DNA replication. Eventually, downstream this 
 cascades to p38 mitogen-activated protein kinase activation, S-phase arrest, and apoptotic 
cell death. This apoptotic program was also induced in human leukemia, breast, prostate 
and head-and-neck cancer cell lines. 
 
Figure (6.1) N-Thiolated β-Lactam Anti-Cancer Mode of Action.[110]
Still unknown is how do N-thiolated β-lactams induce DNA damage in tumor 
cells? Is there a direct interaction between these compounds and DNA? Our labs have 
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shown that these compounds are non-cytotoxic at five times the concentration needed to 
induce DNA damage and inhibit DNA replication in leukemic Jurkat T cells within 2 
hours[110]. If the lactams damage DNA directly then why do they not affect the DNA of 
healthy human cells? What difference between healthy cells and cancer cells can these 
lactams differentiate between? A major difference between these two types of cells is 
intracellular glutathione concentration. It has been shown that tumor cells generate much 
higher concentrations of glutathione that do non-cancerous cells. Much like an infection, 
tumor cells are constantly fighting off oxidation, and by evidence of these increased 
glutathione levels, appear to be doing so more than non-cancerous cells. So, in essence, 
tumor cell redox metabolisms may be more susceptible to inhibition by N-thiolated β-
lactams. As well, the influx roads into tumor cells are known to be quite different from 
other types of cells. Much is yet to be learned about these lactam’s mode of action, 
however the exciting results of induced apoptosis (Figure 6.2) are not diminished. 
 N-Alkylthiolated β–Lactams vs Cancer Cell Lines
Apoptotic Cells
 
Figure (6.2) Apoptotic Effects of N-Thiolated β-Lactams.[110]
 In cancer cell lines, there is also a pattern of activity seen amongst sulfur 
sidechain analogues that is similar to that previously described in Chapter 4 for anti-
MRSA activity. In the case of these cancer cell lines, longer chain lactams have lower 
potencies, as shown with compounds 109a, 109b and 109d in Figure 6.3. (This is 
demonstrated by %Caspase 3 activity values of 100%, 40% and 30% respectively.) 
However, the more potent antibacterial lactams, like 109g, are yet to be tested against 
these cell lines, and lactams with an oxidized sulfur, like N-cyclohexylsulfinyl β-lactam 
109i, have recently shown decreased in vitro growth of breast cancer cell lines by more 
than 50%. 
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Figure (6.3) Trend of Anticancer Activity. 
 
6.3 Conclusions and Future Directions 
 
The rapid procession of resistance to available antimicrobials is depleting the 
current arsenal of antibiotics that remain effective against infections. For decades, no new 
antibacterial targets have been discovered and brought to bear in clinical usage. 
Numerous sulfur compounds are yet to be evaluated for biological activity, and precise 
targets and modes of action of many sulfur reagents are still unexamined. It has been 
proposed that the thiol-disulfide redox metabolisms of infectious organisms might serve 
as a potentially valuable target for development of new anti-infectives. Often, these redox 
systems are extraordinarily divergent from healthy mammalian physiology and therefore 
provide targets where selectivity could be very high. Therefore, N-thiolated β-lactams, 
with their novel mode of action, are excellent drug candidates, as shown here, for the 
treatment of cancer, as well as drug-resistant bacterial and fungal infections. Further 
analogue synthesis does not appear to be warranted, however, with the potential of a 
novel target across a number of systems, further biochemical and in vivo investigations 
are definitely worth exploring. It is the hope of this author that this work may contribute 
to the development of the thiol-disulfide redox as a target of rational drug design.   
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CHAPTER SEVEN 
MATERIALS AND METHODS 
 
 
7.1 Synthetic Procedures 
 
 All chemicals required for the synthesis of N-thiolated β-lactams were purchased 
from one of the following sources: Sigma Aldrich, Fisher Scientific, Acros Organics, TCI 
Organic Chemicals, or Lancaster Research Chemicals. Most were used without further 
purification. Solvents were obtained from Fisher Scientific. Products were purified by 
flash chromatography were done with either J.T.Baker or Whatman flash 
chromatography silica gels (40 µm). NMR spectra were recorded in either CDCl3 or D2O 
as indicated  
7.1.2 Preparation of Imines 
 
N-Anisylimine (105): p-Anisidine, regardless of the source company, was always impure 
upon receipt and therefore required purification by recrystallization from water. (1eq.) 
11.20g (0.0797 moles) of o-chlorobenzaldehyde (103) and  11.00g (0.0894 moles) of 
recrystallized p-anisidine (104) were stirred together neat, at room temperature, open to 
the atmosphere, for a couple of minutes. The solid product was then dissolved in dry 
dichloromethane, dried over magnesium sulfate, and concentrated via rotary evaporation. 
The imine product was quite pure at this stage, but was further purified by 
recrystallization from methanol prior to further use. 
 O
H
Cl O
NH2
CH3
103 104
Cl N
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105  
(E)-N-(2-Chlorobenzylidene)-4-methoxybenzenimine (105): yellow solid; mp 51-52oC; 1H NMR (250 
MHz, CDCl, CDCl3): δ 8.94 (s, 1H), 7.4-6.9 (m, 8H), 3.85 (s, 3H).  
 
7.1.3 Preparation of Acid Chlorides 
Methoxyacetyl chloride (102): Although this acid chloride was available for purchase, 
the price was moderately high and the purity was very poor. Thus, it was preferable to 
synthesized it fresh. Purification of the thionyl is achieved through distillations with 
quinoline and then linseed oil as directed in the literature procedure: Rigby, Chem. Ind., 
1969, 1508. To a dry round bottom flask 30.00g (0.335 moles) of methoxyacetic acid (3) 
was added, followed by dropwise addition of 39.58g (0.335 moles) of thionyl chloride at 
0oC. The mixture was allowed to stir and warm to room temperature overnight. The 
solution was then distilled, open to the atmosphere from 111 to 114oC (literature value = 
112-113oC), to obtain pure product.  
O
OH3C
ClO
OH3C
OH SOCl2
101 102  
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 7.1.4 Preparation of N-4-Anisyl Azetidin-2-ones (β-Lactams) 
N-4-Anisyl azetidin-2-ones (106): In a round bottom flask, 6.00g (0.0245 moles) of N-
Anisylimine 7 and 7.5g (0.0742 moles) of  triethyl amine were dissolved in minimal 
amount of dry dichloromethane and cooled to 0oC. A solution of 2.81g (0.0260 moles) of 
methoxyacetyl chloride in an equal volume of dry dichloromethane was added dropwise 
with stirring. The solution was then heated to reflux, which was maintained overnight. 
After cooling, the solution was poured into an equal volume of water, extracted thrice 
with the dichloromethane, dried over magnesium sulfate and concentrated via rotary 
evaporation. Column chromatography was used for purification, eluting with 
dichloromethane or a mixture of hexanes and ethyl acetate. 
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(±)-(3S,4R)-4-(2-chlorophenyl)-3-methoxy-1-(4-methoxyphenyl)azetidin-2-one (106): white solid; mp 
183-184 °C 1H NMR (250 MHz, CDCl3): δ 7.43 (d, 1H, J = 7.4 Hz), 7.29-7.19 (m, 5H), 6.80 (d, 2H, J = 
9.0 Hz), 5.61 (d, 1H, J = 4.8 Hz), 4.89 (d, 1H, J = 4.8 Hz), 3.73 (s, 3H), 3.27 (s, 3H). 
 
 
7.1.5 Dearylation of N-Anisyl Azetidin-2-ones 
 
N-Protio Azetidin-2-ones (107a): In a round bottom flask 1.00g (0.0035 moles) of N-
anisyl azetidin-2-one 106 was dissolved in a minimal amount of acetonitrile at 0oC. A 
solution of 5.77g (0.01053 moles) of ceric ammonium nitrate, dissolved in a minimal 
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 amount of water, was added dropwise via addition funnel. The reaction was monitored 
via thin layer chromatography (TLC) and was usually complete within 10 minutes. The 
reaction mixture was then poured into three volume equivalents of water and extracted 
thrice with ethyl acetate. The organic extracts were washed sequentially with a 5% 
sodium bicarbonate solution, a 1% sodium bisulfate solution, and a saturated sodium 
chloride solution, then dried over magnesium sulfate and concentrated via rotary 
evaporation. The β-lactam product was purified via column chromatography with a 
mixture of ethyl acetate and hexanes. 
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(±)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxyazetidin-2-one (107a): white solid; mp 93-95oC; 1H NMR 
(250 MHz, CDCl3): δ 7.34 (m, 4H), 6.55 (bs, 1H), 5.27 (d, 1H, J = 4.6Hz), 4.85 (d, 1H, J = 4.6Hz), 3.29 (s, 
3H). 
(±)-(3S,4R)-3-Methoxy-4-phenylazetidin-2-one (107b): white solid; mp 130-131oC; 1H NMR (250 MHz, 
CDCl3): δ 7.35 (m, 5H), 6.24 (bs, 1H), 5.30 (d, 1H, J = 4.6 Hz), 4.87 (dd, 1H, J = 3.4, 1.2 Hz), 3.30 (s, 3H). 
(±)-(3S,4R)-3-Acetoxy-4-(2-chlorophenyl)azetidin-2-one (107c): white solid; mp 100-101oC; 1H NMR 
(250 MHz, CDCl3): δ 7.37 (m, 4H), 5.30 (d, 1H, J = 4.6Hz), 4.87 (t, 1H, J = 3.8Hz), 3.29 (s, 3H), 1.59 (s, 
3H). 
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 7.1.6 Preparation of Phthalimide-based Sulfur Transfer Reagents (111) 
 
Method 1: In dry benzene, chlorine gas was bubbled until the increase in weight equaled  
0.93g (0.01313 moles). This was then added to a round bottom flask containing 1.00g 
(0.01313 moles) 2-propanethiol in a minimal quantity of benzene and then sealed at 0oC 
with stirring for 1 hour. The solution was then added dropwise to a second round bottom 
flask containing a slurry of 1.93g (0.01313 moles) phthalimide (110) and 2.89g (0.02232 
moles) of Hunig’s base and allowed to reach room temperature over 2 hours with stirring. 
The solution was then poured into water, extracted thrice with benzene, dried over 
magnesium sulfate and concentrated via rotary evaporation. This often generated a pure 
product. When unreacted phthalimide remained, triteration with chloroform dissolved the 
product nicely, leaving the starting material to be filtered off. When present, other 
impurities were removed by recrystallization with methanol or column chromatography. 
N
O
O
S
R
NH
O
O
R-S-Cl
 DIPEA
111110  
2-(Methylthio)isoindoline-1,3-dione (111a): white solid; 1H NMR (250 MHz, CDCl3): mp 178-180oC; δ 
7.82 (m, 4H), 3.77 (s, 3H). 
2-(Ethylthio)isoindoline-1,3-dione (111b): white solid; mp 158-160oC; 1H NMR (250 MHz, CDCl3): δ 
7.86 (m, 4H), 2.92 (q, 2H, J = 7.34 Hz), 1.56 (t, 3H, J = 8.1 Hz). 
2-(Propylthio)isoindoline-1,3-dione (111c): white solid; 77-78oC; 1H NMR (250 MHz, CDCl3): δ 7.87 
(m, 4H), 2.86 (t, 2H, J = 7.3 Hz), 1.62 (m, 2H), 1.04 (t, 3H, J = 7.3 Hz) 
2-(Butylthio)isoindoline-1,3-dione (111d): white solid; mp 189-190oC; 1H NMR (250 MHz, CDCl3): δ 7.8 
(m, 4H), 2.85 (t, 2H, J = 7.4 Hz), 1.61 (m, 2H), 1.42 (m, 2H), 0.91 (t, 3H, J = 5.0Hz). 
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2-(Isopropylthio)isoindoline-1,3-dione (111f): white solid; mp 61-62oC; 1H NMR (250 MHz, CDCl3): δ 
7.8-7.5 (m, 4H), 4.9 (m, 1H), 2.17 (d, 6H, J = 6.9Hz). 
(+)-2-(sec-Butylthio)isoindoline-1,3-dione (111g): white solid; mp 43-45oC; 1H NMR (250 MHz, CDCl3): 
δ 7.83 (m, 4H), 3.21 (m, 1H), 1.55 (m, 2H), 1.24 (d, 3H, J = 6.8 Hz), 1.04 (t, 3H, J = 7.3 Hz).  
2-(Cyclohexylthio)isoindoline-1,3-dione (111i): white solid; mp 92-94oC; 1H NMR (250 MHz, CDCl3): δ 
7.80 (m, 4H), 3.05 (m, 1H), 1.90-1.25 (m, 11H). 
2-(Phenylthio)isoindoline-1,3-dione (111j): white solid; mp 149-155oC; 1H NMR (250 MHz, CDCl3): δ 
8.0-6.8 (m, 9H). 
2-(Benzylthio)isoindoline-1,3-dione (111k): white solid; mp 165-168oC; 1H NMR (250 MHz, CDCl3): δ 
7.9-7.5 (m, 4H), 7.31 (m, 5H), 1.75 (s, 2H). 
(+)-2-(1-Phenylethylthio)isoindoline-1,3-dione (111l): white solid; mp 100-104oC; 1H NMR (250 MHz, 
CDCl3): δ 7.20 (m, 9H), 3.67 (q, 1H, J = 6.2), 1.76 (d, 3H, J = 5.0). 
2-(2-Napthylthio)isoindoline-1,3-dione (111m): white solid; mp 120-128oC; 1H NMR (250 MHz, CDCl3): 
δ 7.65 (m, 11H). 
 
Method 2: In dry benzene 0.1g (0.0004424 moles) of N-bromophthalimide was dissolved 
in a minimal quantity of benzene and stoppered at 0oC with stirring. The solution was 
then added dropwise to a second round bottom flask containing a solution of 0.034g 
(0.0004424 moles) of 1-butnaethiol and 0.06g (0.0004424 moles) of triethyl amine. The 
mixture was allowed to achieve room temperature over 2 hours with stirring. The solution 
was then poured into an equal volume of water, extracted thrice with equal volumes of 
benzene, dried over magnesium sulfate and concentrated via rotary evaporation. This 
often generated a fairly pure product. Unreacted phthalimide was removed via triteration 
with chloroform which dissolved the product nicely, leaving the starting material to be 
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filtered off. Also present, were other impurities which were removed via recrystallization 
with methanol and column chromatography. 
2-(Octylthio)isoindoline-1,3-dione (111e): white solid; mp 55-58oC; 1H NMR (250 MHz, CDCl3): δ 7.88 
(m, 4H), 2.91 (t, 2H, J = 7.3 Hz), 1.76-1.28 (m, 12H), 0.89 (t, 3H, J = 6.4 Hz). 
2-(tert-Butylthio)isoindoline-1,3-dione (111h): white solid; mp 130-133oC; 1H NMR (250 MHz, CDCl3): 
δ 7.87 (m, 4H), 1.36 (s, 9H). 
 
Method 3: In a round bottom flask was added 0.0061g (0.0000272 moles) of (anthracen-
10-yl)methanethiol, 0.0035g (0.0000354 moles) potassium carbonate, and 0.0040g 
(0.0000272 moles) phthalimide in 5ml of reagent grade acetone. The vessel was sealed 
and the liquid meniscus was submerged below an active sonication bath for 24 hours. The 
solution was concentrated via rotary evaporation and re-dissolved in 10ml of 
dichloromethane. The solution was washed with and equal volume of water, dried over 
magnesium sulfate and concentrated via rotary evaporation. The product yields were very 
low and purification was not attempted for loss of all product. 
2-((Anthracen-10-yl)methylthio)isoindoline-1,3-dione (111n):  white solid; 1H NMR (250 MHz, CDCl3): 
δ 8.38-7.17 (m, 13H), 3.12 (s, 2H). 
 
Method 4: In a round bottom flask was added the thioester dissolved in a minimal 
quantity of carbon tetrachloride and cooled to 0oC with stirring. A solution of sulfuryl 
chloride in an equal volume of carbon tetrachloride was then added dropwise and the 
solution was allowed to come to room temperature with stirring over 30 minutes. The 
solution was then added dropwise into a slurry of phthalimide and Hunig’s base in an 
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equal volume of carbon tetrachloride cooled to 0oC with stirring. After the mixture was 
allowed to warm to room temperature over 3 hours with stirring, 40 ml of water was then 
added and the mixture was then allowed to stir at high speed for 20 min. The mixture was 
filtered and the solid washed with 40 ml more of water. The solid was then triterated with 
chloroform and the dissolved product was dried over magnesium sulfate and concentrated 
via rotary evaporation. 
2-(7-(Methyl2-(2-chloro-6-methoxy-3-oxo-3H-xanthen-9-yl)benzoate)thio)isoindoline-1,3-dione 
(111o): white solid; mp 140-146oC; 1H NMR (250 MHz, CDCl3): δ 9.2-7.3 (m, 9H), 6.05 (s, 1H), 5.35 (s, 
1H), 3.8 (s, 3H), 3.05 (s, 3H). 
2-(Polystyrenylthio)isoindoline-1,3-dione (164): light brown powder; IR 3015 (aromatic C-H stretch), 
2980 (aliphatic C-H stretch), 1490, 1450 (C=O stretches). 
 
7.1.7 Preparation of N-Thiolated Azetidin-2-ones 
N-Thiolated azetidin-2-ones (109j): In a round bottom flask was added 0.005g 
(0.0000236 moles) N-protio β-lactam 107, 0.0067g (0.000236 moles) of N-
phenylthiolated phthalimide and 0.0119g (0.000118 moles) of triethylamine, in a minmal 
quantity of dichloromethane. The solution was refluxed and followed via TLC. Reaction 
was complete after 12 hours. After cooling, the solution was poured into an equal volume 
of water, washed with aqueous solutions of 5% sodium bicarbonate, 1% sodium bisulfate, 
and saturated sodium chloride. The extracts were then dried over magnesium sulfate and 
concentrated via rotary evaporation. Phthalimide was removed via triteration with 
chloroform and  the remaining impurities were removed via column chromatography, 
eluting with either dichloromethane.  
 N
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(±)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-(methylthio)azetidin-2-one (109a) white crystal; mp 71-
73 °C; 1H NMR (250 MHz, CDCl3): δ 7.35 (d, 1H, J = 7.4 Hz), 7.24 (m, 3H), 5.29 (d, 1H, J = 4.9 Hz), 
4.80 (d, 1H, J = 4.9 Hz), 3.16 (s, 3H), 2.40 (s, 3H); 13C NMR (63 MHz, CDCl3): δ 170.4, 133.8, 131.4, 
129.6, 128.9, 126.8, 86.7, 62.7, 58.9, 21.8.  
(+)-(3S,4R)-4-(2-Chlorophenyl)-N-ethylthio-3-methoxyazetidin-2-one (109b): white solid; mp 68-70oC;  
1H NMR (250MHz, CDCl3) δ 7.34 (4H, m), 5.33 (1H, d, J = 5.0 Hz), 4.88 (1H, d, J = 5.0 Hz), 3.20 (3H, s), 
1.35 (2H, q, J = 10.0 Hz), 0.92 (3H, t, J = 6.8 Hz); 13C NMR (63 MHz, CDCl3): δ 172.5, 142.1, 137.5, 
130.8, 128.8, 128.4, 87.5, 70.5, 46.7, 34.4, 22.0.  
(±)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-(propylthio)azetidin-2-one (109c) colorless oil; 1H NMR 
(250 MHz, CDCl3): δ 7.6-7.2 (m, 4H), 5.45 (d, 1H, J = 4.9Hz), 5.09 (d, 1H, J = 4.9Hz), 3.21 (s, 3H), 2.49 
(m, 2H), 1.55 (m, 2H), 0.82 (t, 3H, J = 6.9Hz); 13C NMR (63 MHz, CDCl3): δ 171.0, 133.6, 128.8, 128.3, 
86.3, 66.9, 58.3, 38.2, 30.8, 21.5, 13.6. 
(+)-(3S,4R)-N-Butylthio-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (109d): light yellow, viscous oil, 
1H NMR (250MHz, CDCl3) δ 7.30 (4H, m), 5.35 (1H, d, J = 4.9Hz), 4.89 (1H, d, J = 4.9Hz), 3.23 (3H, s), 
2.85 (2H, t, J = 7.0), 1.60 (4H, m), 0.91 (3H, t, J = 7.3Hz); 13C NMR (63 MHz, CDCl3): δ 176.5, 134.0, 
132.1, 129.7, 129.0, 126.9, 86.8, 64.8, 58.1, 48.0, 12.3. 
(+)-(3S,4R)-4-(2-Chlorophenyl)-N-octylthio-3-methoxyazetidin-2-one (109e): white solid, 1H NMR 
(250MHz, CDCl3) δ 7.35 (4H, m), 5.35 (1H, d, J = 4.9 Hz), 4.89 (1H, d, J = 4.9 Hz), 3.23 (1H, m), 2.77 
(2H m), 1.64-1.26 (12H, m), 0.88 (t, 3H, J = 6.2 Hz); 13C NMR (63 MHz, CDCl3): δ 167.8, 132.5, 131.1, 
127.5, 127.0, 80.3, 52.7, 43.7, 28.0, 26.0, 24.5, 22.3, 18.9. 
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(+)-(3S,4R)-4-(2-Chlorophenyl)-N-isopropylthio-3-methoxyazetidin-2-one (109f): light yellow paste, 
mp 30-38oC; 1H NMR (250MHz, CDCl3) δ 7.34 (4H, m), 5.39 (1H, d, J = 4.9 Hz), 4.95 (1H, d, J = 4.9 
Hz), 3.27 (1H, m), 3.25 (3H, s), 1.27 (6H, d, J = 5.7Hz); 13C NMR (63 MHz, CDCl3): δ 171.3, 133.2, 
128.9, 127.0, 87.1, 65.2, 59.7, 49.4, 34.0, 30.1, 28.5, 25.8, 21.5. 
(+)-(3S,4R)-N-sec-Butylthio-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (109g): light yellow, viscous 
oil, + cis mixture. 1H NMR (250MHz, CDCl3) δ 7.4 (1H, d, J = 7.4 Hz), 7.3 (3H, m), 5.3 (1H, d, J = 4.7 
Hz), 4.9 (1H, d, J = 4.8 Hz), 3.2 (3H, s), 3.0 (1H, m), 1.48 (1H, m), 1.2 (3H, dd, J = 6.8, 4.9 Hz), 0.94 (3H, 
q, J = 6.0 Hz); 13C NMR (63 MHz) δ 171.0, 133.8, 131.4, 129.5, 128.9, 126.8, 86.3, 64.1, 58.8, 48.1, 28.1, 
19.0, 18.6, 11.1. 
(+)-(3S,4R)-N-tert-Butylthio-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (109h): white solid, 1H NMR 
(250MHz, CDCl3) δ 7.34 (4H, m), 5.50 (1H, d, J = 4.8 Hz), 4.99 (1H, d, J = 4.8 Hz), 3.25 (3H, s), 1.35 
(9H, s); 13C NMR (63 MHz, CDCl3): δ 166.0, 133.0, 129.0, 88.0, 65.0, 60.0, 44.0, 34.0, 31.0, 27.0, 19.0. 
(+)-(3S,4R)-4-(2-Chlorophenyl)-N-cyclohexylthio-3-methoxyazetidin-2-one (109i): brown solid; mp 78-
79oC; 1H NMR (250MHz, CDCl3) δ 7.34 (4H, m), 5.35 (1H, d, J = 4.9 Hz), 4.93 (1H, d, J = 4.9 Hz), 3.24 
(3H, s), 3.05 (1H, m), 2.01-1.41. (10H, m); 13C NMR (63 MHz, CDCl3): δ 171.3, 133.5, 128.9, 128.7, 
128.3, 85.2, 67.6, 58.3, 49.5, 32.2, 30.9, 25.6, 25.4. 
(+)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-phenylthioazetidin-2-one (109j): light yellow, oily solid, 
mp 60-62oC 1H NMR (250MHz, CDCl3) δ 7.34 (9H, m), 5.35 (1H, d, J = 5.0Hz), 4.91 (1H, d, J = 5.0Hz), 
3.25 (3H, s); 13C NMR (63 MHz, CDCl3): δ 172.0, 137.0, 135.0, 134.0, 132.0, 130.0, 129.0, 128.0, 127.0, 
125.0, 82.0, 59.0, 48.0. 
(+)-(3S,4R)-N-Benzylthio-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (109k): light yellow, oily solid; 
mp 68-70oC; 1H NMR (250MHz, CDCl3) δ 7.22 (9H, m), 5.30 (1H, d, J = 4.7 Hz), 4.55 (1H, d, J = 4.8 
Hz), 3.16 (3H, s), 1.25 (3H, s); 13C NMR (63 MHz, CDCl3): δ 179.0, 142.0, 138.0, 136.0, 135.0, 134.0, 
132.0, 130.0, 128.0, 126.0, 88.0, 59.0, 48.0, 40.0. 
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(+)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-(1-phenylethylthio)-azetidin-2-one (109l): white solid; 
mp 65-67oC; 1H NMR (250MHz, CDCl3) δ 7.56 (9H, m), 5.25 (1H, d, J = 4.2 Hz), 4.84 (1H, d, J = 4.2 Hz), 
3.27 (3H, s), 3.01 (2H, m), 0.93 (3H, d, J = 7.1 Hz); 13C NMR (63 MHz, CDCl3): δ 168.9, 164.1, 139.6, 
138.3, 134.5, 133.5, 118.5, 79.9, 51.4, 43.7, 40.8, 29.3. 
(+)-(3S,4R)-4-(2-Chlorophenyl)-3-hydroxy-N-naphthylthioazetidin-2-one (109m1): white solid; 1H 
NMR (250MHz, CDCl3) δ 7.9-7.2 (11H, m), 5.3 (2H, m); 13C NMR (63 MHz, CDCl3): δ 172.0, 142.0, 
135.0, 133.0, 132.0, 131.0, 129.0, 128.0, 127.0, 126.0, 125.0, 124.0, 123.0, 122.0, 81.0, 58.0. 
(+)-(3S,4R)-4-(2-Chlorophenyl)-3-methoxy-N-napthylthioazetidin-2-one (109m): yellow solid, 1H 
NMR (250MHz, CDCl3) δ 8.13-7.19 (11H, m), 5.35 (1H, d, J = 5.0 Hz), 4.91 (1H, d, J = 5.0 Hz), 3.24 (3H, 
s); 13C NMR (63 MHz, CDCl3): δ 170.0, 142.0, 130.0, 134.0, 132.0, 131.0, 130.0, 129.0, 128.0, 127.0, 
126.0, 125.0, 123.0, 121.0, 82.0, 58.0, 55.0. 
(+)-(3S,4R)-N-((Anthracen-10-yl)methylthio)-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (109n): 
pink solid, 1H NMR (250MHz, CDCl3) δ 7.48-7.19 (13H, m), 5.25 (1H, d, J = 4.8 Hz), 4.81 (1H, d, J = 4.8 
Hz), 4.078 (2H, s), 3.25 (3H, s). 
(+)-(3S,4R)-N-(R)(sec-Butylthio)-3-methoxy-4-phenylazetidin-2-one (152): white oil; 1H NMR 
(250MHz, CDCl3) δ 7.29 (m, 5H), 5.94 (d, 1H, J = 4.9 Hz), 5.01 (d, 1H, J = 4.9), 2.99 (m, 1H), 1.47 (m, 
2H), 1.28 (d, 3H, J = 6.8 Hz), 0.94 (t, 3H, J = 7.4 Hz). 
(-)-(3S,4R)-N-(R)(sec-Butylthio)-3-methoxy-4-phenylazetidin-2-one (153): white oil; 1H NMR 
(500MHz, CDCl3) δ 7.30 (m, 5H), 5.87 (d, 1H, J = 3.5 Hz), 4.94 (d, 1H, J = 4.0 Hz), 2.90 (m, 1H), 1.62-
1.40 (m, 2H), 1.12 (d, 3H, J = 6.5 Hz), 0.90 (t, 3H, J = 8.0 Hz). 
(+)-(3R,4S)-N-(S)(sec-Butylthio)-3-methoxy-4-phenylazetidin-2-one (154): white oil; 1H NMR 
(250MHz, CDCl3) δ 7.32 (m, 5H), 5.94 (d, 1H, J = 4.9 Hz), 5.01 (d, 1H, J = 4.9 Hz), 2.97 (m, 1H), 1.56 (m, 
2H), 1.18 (d, 3H, J = 6.9 Hz), 0.97 (t, 3H, J = 7.4 Hz). 
(-)-(3R,4S)-N-(S)(sec-Butylthio)-3-methoxy-4-phenylazetidin-2-one (155): white oil; 1H NMR 
(250MHz, CDCl3) δ 7.29 (m, 5H), 5.94 (d, 1H, J = 4.9 Hz), 5.01 (d, 1H, J = 4.9 Hz), 2.99 (m, 1H), 1.51 (m, 
2H), 1.28 (d, 3H, J = 6.75 Hz), 0.94 (t, 3H, 7.4 Hz). 
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7.1.8 Preparation of Thioesters 
Method 1 (Mitsunobu Reaction): In a round bottom flask was added 9ml (0.04506 
moles) of diisopropyl azodicaroxylate (DIAD) and 12.16g (0.04506 moles) of 
triphenylphosphine were combined in THF at 0oC, under nitrogen with stirring. This 
solution was allow to stir for 30 min, or until a white precipitate formed. Then a solution 
of 3.43g (0.04506 moles) thiolacetic acid and 3.25g (0.0225 moles) of 2-nonanol in a 
minimal quantity of THF was added carefully, dropwise. After work-up it was very 
difficult to remove all of the triphenylphosphine as it shared a close Rf value with the 
desired products. 
Method 2 (Substitution): In a round bottom flask was added (1 eq.) an alkyl halide in a 
minimal amount of benzene under nitrogen, at 0oC with stirring. To this, a solution, of 
(1eq.) triethylamine and (1 eq.) thiolacetic acid in enough benzene, was added dropwise. 
The solution was allowed to come to room temperature over 3 hours with stirring. The 
reaction mixture was then poured into an equivalent portion of water, extracted with 
benzene, dried over magnesium sulfate and concentrated via rotary evaporator. Continued 
exposure to a stream of nitrogen successfully removed any remaining triethylamine. 
 
7.1.9 Preparation of N-Sulfoxylated β-Lactams 
Method 1 H2O2 (157b): Inspired via Prinzbach and Netscher, Synthesis, 1987, 683-688. 
In a round bottom flask was added 0.0135g (0.0000415 moles) an N-cyclohexylthiolated 
β-lactam in a minimal amount of glacial acetic acid at 0oC with stirring. To this, a 
solution, of 0.008g (0.0000415 moles) of 30% hydrogen peroxide in few drops of glacial 
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acetic acid, was added dropwise. The solution was allowed to come to room temperature 
over 3 hours with stirring. The reaction mixture was then poured into an equivalent 
portion of water, extracted with three equivalent volumes of benzene, washed with water 
until the washings were at neutral pH, as observed via pH paper, dried over magnesium 
sulfate and concentrated via rotary evaporation.  
 
(+)-(3S,4R)-N-Cyclohexylsulfinyl-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (157b): white oil, 1H 
NMR (250MHz, CDCl3) δ 7.41 (8H, m), 5.85 (1H, d, J = 6.0Hz), 5.71 (1H, d, J = 5.6), 4.94 (1H, d, J = 
6.0Hz), 4.91 (1H, d J = 6.0Hz), 3.75 (2H, m), 3.29 (3H, s), 3.23 (3H, s), 2.72 (2H, m), 2.2-0.80 (20H, m); 
13C NMR (63 MHz, CDCl3): δ 171.4, 133.6, 130.9, 130.8, 129.3, 123.5, 83.4, 61.6, 53.2, 50.5, 37.4, 29.9, 
25.6. 
(+)-(3S,4R)-N-Phenylsulfinyl-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (157a): white oil, 1H NMR 
(250MHz, CDCl3) δ 7.30 (m, 9H), 5.18 (bs, 1H), 4.80 (bs, 1H), 3.25 (bs, 1H); 13C NMR (63 MHz, CDCl3): 
δ 168.9, 164.1, 131.4, 128.1, 131.5, 118.0, 113.9, 108.8, 79.7, 54.7, 43.9. 
 
Method 2 mCPBA: In a round bottom flask was added 0.20 g (0.00085 moles) an N-sec-
butylthiolated β-lactam in a minimal amount of diethyl ether at 0oC with stirring. To this, 
a solution, of 0.14 g (0.00080 moles) meta-chloroperoxybenzoic acid in a minimal 
amount of diethyl ether, was added dropwise. The solution was monitored via thin layer 
chromatography. The reaction mixture was then poured into an equivalent portion of 
water, extracted thrice with equivalent volumes of benzene, washed twice with water, 
dried over magnesium sulfate and concentrated via rotary evaporation. 
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(+)-(3S,4R)-N-sec-Butylsulfinyl-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (157c): dark brown paste, 
mp 35-43oC; 1H NMR (250 MHz, CDCl3) δ 7.32 (4H, m), 5.38 (1H, d, J = 4.9 Hz), 4.94 (1H, d, J = 4.9 
Hz), 3.11 (2H, m), 2.11 (3H, s), 1.75-0.96 (8H, m); 13C NMR (63 MHz, CDCl3): δ 171.2, 149.8, 131.4, 
129.5, 129.0, 126.8, 86.5, 74.1, 58.8, 48.1, 28.1, 19.0, 14.6, 11.2. 
 
 
7.1.10 Preparation of N-Sulfonylated β-Lactams 
 
Method: Identical to 7.1.9 Method 1. 
(+)-(3S,4R)-N-Cyclohexylsulfonyl-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (158b): white, oily 
solid; mp 152-158oC; 1H NMR (250 MHz, CDCl3) δ 7.47 (m, 4H), 5.79 (d, 1H, J = 5.0 Hz), 4.97 (d, 1H, J 
= 4.6 Hz), 3.29 (s, 3H), 3.12 (m, 1H), 2.20-0.86 (m, 10H); 13C NMR (63 MHz, CDCl3): δ 174.9, 143.8, 
127.9, 125.8, 120.1, 118.5, 84.6, 61.9, 52.0, 45.2, 40.1, 34.9, 33.6. 
(+)-(3S,4R)-N-Phenylsulfonyl-4-(2-chlorophenyl)-3-methoxyazetidin-2-one (158a): white oil, 1H NMR 
(250 MHz, CDCl3) δ 7.96-7.16 (9H, m), 5.70 (1H, d, J = 5.6 Hz), 4.82 (1H, d, J = 5.6 Hz), 3.35 (3H, s) 13C 
NMR (63 MHz, CDCl3): δ 168.9, 164.1, 144.4, 139.5, 134.2, 128.0, 125.7, 119.0, 79.9, 54.5, 43.8. 
 
7.1.11 Preparation of a β-Lactam Sulfonic Acid 
 
Method (160): Literature Procedure Cimarusti, C. Tetrahedron, 1983, 39, 2577. In a 
round bottom flask a solution 0.01g (0.472 mmol) of N-protio β-lactam in 2 ml of freshly 
distilled dichloromethane and 2 ml of dry DMF was stirred with 0.014g (0.00944 moles) 
of 50% sulfur trioxide-pyridine under nitrogen at room temperature for 2 hours. The 
solution was concentrated via rotary evaporator. The resultant salt was ion exchanged for 
a potassium salt. Application of this salt to column chromatography afforded the 
necessary protonation to afford the sulfonic acid in a pure form. 
 
  155
(+)-(3S,4R)-2-(2-Chlorophenyl)-3-methoxy-4-oxoazetidine-1-sulfonic acid (160): dark brown oil, 1H 
NMR (250MHz, CDCl3) δ 7.32 (4H, m), 5.69 (1H, d, J = 4.9 Hz), 4.98 (1H, d, J = 4.9 Hz), 3.32 (2H, m), 
0.89 (1H, s); 13C NMR (63 MHz, CDCl3): δ 179.9, 145.2, 137.7, 131.0, 122.7, 83.4. 55.2. 43.3. 
 
 
7.1.12 De-Acetylation of a C3 Acetoxy Substituted β-Lactam 
 
Method: To a round bottom flask 0.184g (0.0329 moles) of potassium hydroxide was 
dissolved in a minimal quantity of methanol. To this solution was added a solution of 
0.787g (0.0329 moles) of (+)-(3S,4R)-4-(2-chlorophenyl)-3-acetoxy-1-azetidin-2-one in 
enough 0oC. The solution was allowed to warm to room temperature over night with 
stirring. The solution was then concentrated via rotary evaporation, re-dissolved in 
methylene chloride, washed with water until the washing were neutral pH via pH paper, 
dried over magnesium sulfate, and concentrated via rotary evaporation.  
(+)-(3S,4R)-4-(2-Chlorophenyl)-3-hydroxy-N-azetidin-2-one (108OH): white solid; mp 204-205oC; 1H 
NMR (250 MHz, CDCl3): δ 7.30 (m, 4H), 6.82 (s, 1H), 5.64 (d, 1H, J = 5.2 Hz), 5.34 (d, 1H, J = 4.9 Hz), 
3.79 (s, 3H). 
 
7.1.13 Re-Acetylation of a C3 Hydroxy Substituted β-Lactam. 
Method: To a round bottom flask was added 10.0ml (excess) of pyridine and 0.119ml 
(0.0001283moles) of acetic anhydride and chilled to 0oC. To this solution was added 
0.0345g (0.0001283 moles) of (-)-(3S,4R)-4-(2-Chlorophenyl)-3-hydroxy-N-(4-
methoxyphenyl)azetidin-2-one. The resultant solution was stirred for 1 hour at 0oC and 
was allowed to stir overnight at room temperature, then poured into ice water. The 
mixture was filtered to yield a pure white solid. 
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(-)-(3S,4R)-3-Acetoxy-4-(2-chlorophenyl)-N-(4-methoxyphenyl)azetidin-2-one (p152): white solid; mp 
165-167oC;  1H NMR (250 MHz, CDCl3): δ 7.30 (m, 8H), 5.94 (d, 1H, J = 4.9 Hz), 5.34 (d, 1H, J = 4.9 
Hz), 3.76 (s, 3H), 1.68 (s, 3H). 
 
7.1.14 Dansylation  
Method: To a round bottom flask was added 0.005 g (0.0261 mmol) to a minimal 
quantity of tetrahydrofuran for dissolution. The flask was then chilled to 0oC with 
stirring. To this was added 0.002 (0.0522 mmol) of sodium hydride, pre-dissolved in 
aminimal quantity of tetrahydrofuran. This solution was allowed to stir for 30 minutes. 
This solution was then added to 0.007 (0.0261 mmol) of dansyl chloride, pre-dissolved in 
a minimal quantity of tetrahydrofuran. This mixture was allowed to stir for an additional 
30 minutes. The remaining sodium hydride was quenched with slightly wet methanol. 
The reaction mixture was then poured into an equal volume of water and extracted thrice 
with equal portions of tetrahydrofuran. The organic layers were combined and washed 
with an equal volume of water. The organic extracts were then dried over magnesium 
sulfate and concentrated via rotary evaporation. 
2-(2-Chlorophenyl)-4-oxoazetidin-3-yl 5-(dimethylamino)naphthalene-1-sulfonate:  yellow solid; mp 
135-140oC; 1H NMR (250 MHz, CDCl3): δ 8.48 (b, 1H), 8.25 (b, 1H), 8.05 (b, 1H), 7.52 (b, 1H), 7.40 (b, 
1H), 7.30 (b, 2H), 6.90 (b, 1H), 6.75 (b, 1H), 6.60 (b, 1H), 5.25 (b, 1H), 4.80 (b, 1H), 2.85 (s, 6H).  
 
7.2 Microbiological Test Procedures 
 
The following bacteria were used for the antimicrobial evaluation of N-thiolated 
β-lactams: Bacillus anthracis (Sterne strain), Bacillus cereus (ATCC 14579), Bacillus 
coagulans (USF 546), Bacillus globigii (Department of Defense Reagents Program), 
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Bacillus megaterium (ATCC 14581), Bacillus subtilis (19569), Bacillus thuringensis 
(ATCC 10792), Bacteroides fragalis (obtained from Smith-Kline Laboratory), Candida 
albicans (clinical isolate), Candida tropicalis (clinical isolate), Enterobacter cloace 
(environmental isolate, USF510), Enterococcus gallinarium (ATCC 49573), 
Enterococcus faecalis (ATCC 19433), Enterococcus casseliflavus (ATCC 700327), 
Enterococcus durans (ATCC 6056), Enterococcus avirum (ATCC 14025), Enterococcus 
saccharolyticus (ATCC 43076), Escherichia coli (ATCC 23590), Haemophilus 
influenzae (USF 561), Klebsiella pneumoniae (USF 512), Lactococcus lactis (ATCC 
11454), Listeria monocytogenes (ATCC 19115), Micrococcus luteus (environmental 
isolate, USF681), Niesserria gonnorheae (obtained from the Tampa Branch State 
Laboratory, β-lactamase positive, USF 662), Pseudomonas aeruginosa (ATCC 15442), 
Salmonella typhimurium (obtained from University of South Florida Medical Clinic, USF 
515), Serratia marcescens (ATCC 29634), Staphylococcus aureus USF525 (ATCC 
25923) Staphylococcus aureus USF652-658 (obtained from Lakeland Regional Medical 
Center, β-lactamase positive), Staphylococcus epidermidis (environmental isolate, 
USF528), Staphylococcus saprophyticus (ATCC 35552), Staphylococcus simulans 
(ATCC 11631), Staphylococcus capitis (ATCC 35661), Staphylococcus cohnii (ATCC 
35662), Staphylococcus lentus (ATCC 700403), Staphylococcus lugdunensis (ATCC 
700328), Staphylococcus xylosus (ATCC 29971), Streptococcus pyrogenes, 
Streptococcus agalactiae, Vibrio cholerae (biotype E1 Tor Ogawa, cholera toxin 
positive, CDC E5906),  
 
  158
7.2.1 Antimicrobial Susceptibility Testing  
Culture preparation: From a freezer stock in tryptic soy broth (Difco Laboratories, 
Detroit, MI) and 20% glycerol, a culture of each organism was grown on tryptic soy agar 
(TSA) plates (Becton-Dickinson Laboratories, Cockeysville, MD) at 37°C for 24 hours. 
A 108 suspension was then made in sterile phosphate buffered saline (pH 7.2) and 
swabbed across fresh TSA plates.  
Disc method: From each 1mg/ml stock solution in dimethyl sulfoxide (DMSO), sterile 
6mm paper discs (Becton-Dickinson Laboratories, Cockeysville, MD) were impregnated 
with 20 µl of the test compounds. At this concentration, the microliter quantity is 
equivalent to the micrograms in solution. The discs were allowed to dry in a biohazard 
safety hood then placed onto the inoculated TSA plates. The plates were incubated for 24 
hours at 37°C and the antimicrobial susceptibilities were determined by measuring the 
zones of growth inhibition around each disc.  
Well method: A 108 standardized cell count suspension was then made in sterile 
phosphate buffered saline (pH 7.2) and swabbed across fresh TSA plates. Circular wells 
(6 mm in diameter) were cut into the inoculated plates and 20 µL of a 1 mg/ml stock 
solution of the test lactam in dimethylsulfoxide (DMSO) was pipetted into the wells. The 
plates were incubated for 24 hours at 37°C and the antimicrobial susceptibilities were 
determined by measuring the zones of growth inhibition around each well.  
 
7.2.2 MIC Calculations  
Media preparation: The minimum inhibitory concentrations were determined by the 
agar plate dilution (need reference). The test media were prepared in 24 well plates 
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(Costar 3524, Cambridge, MA) by adding a known concentration of the test drug in 
DMSO together with a solution of Mueller-Hinton II agar (Becton-Dickinson 
Laboratories, Cockeysville, MD) for a total volume of 1 ml in each well. Calculations of 
the overall concentration of antibiotic in the wells were standardized by measuring from a 
1mg/ml stock solution of the test drug. At this concentration, the microliter quantity is 
equivalent to the micrograms in solution. The amount of agar solution added to the wells 
was determined by adding to the quantity of test drug in each well to give a combined 
volume of 1 ml. Following preparation of the well plates, the media were allowed to 
solidify at room temperature for 24 hours before inoculation.  
Inoculation: From an 24 hour culture of each organism on tryptic soy agar (TSA) plates 
(Becton-Dickinson Laboratories, Cockeysville, MD), the Staphylococcal strains were 
grown overnight in 5 ml of tryptic soy broth (Difco Laboratories, Detroit, MI) at 37°C. 
One microliter of each culture was then applied to the appropriate well of agar and 
incubated at 37°C overnight. After 24 hr, the MICs were determined by examining the 
wells for growth.  
  
7.2.4 Glucose Uptake / Respiration Study  
A fresh 200 ml culture of an 106 cfu/ml suspension of S. aureus (ATCC 25923) 
was precipitated via centrifugation. The solid contents were separated from the 
supernatant and washed with a phosphate buffer solution (PBS). The mixture was then 
precipitated again and the supernatant removed. The cells were resuspended in 10 ml of 
PBS to an approximate concentration of 5 X 109 cells/ml. This is the bacteria stock 
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solution. The solutions of 1 µM horseradish peroxidase (HRP), and glucose oxidase were 
prepared. 4mL of 5X buffer was added to 16 mL of DI water to generate a 1X buffer. 
Then, 1ml of 1X buffer was used to dissolve 5.9 mg of glucose. Then 50 µL of this 
solution was diluted in 3950µL of 1X buffer. This is the glucose stock solution. 
Next, 1mg of lactam was dissolved in 10mL of DMSO/water. This is the lactam 
stock solution. 1.2 mg of glutathione was added to 10 mL of water. This is the 
glutathione stock solution. Then 1.2 mg of erythromycin was dissolved in 10 ml 
DMSO/water. This is the erythromycin stock solution. Finally, 1.2 mg of dithiothritol 
(DTT) was dissolved in 10ml DMSO/water. This is the DTT stock solution. The 
experimental tubes were then set up as follows.  
 
Experiment tubes: 1)Tube 1. Maximum Glucose Uptake. 
    Add 1mL of Bacteria Stock Solution  
    Add 303µL of Glucose Stock Solution 
    Add 3.99mL of buffer. 
     
    2)Tube 2. Just Sugar. 
    Add 303µL of Glucose Stock Solution 
    Add 4.99mL of buffer. 
 
    3)Tube 3. Sugar with Lactam. 
    Add 303µL of Glucose Stock Solution 
    Add 1mL of Lactam Stock Solution 
    Add 3.99mL of buffer. 
 
    4)Tube 4. Test 0.5 MIC (0.25µg/mL) 
    Add 303µL of Glucose Stock Solution 
    Add 0.250mL of Lactam Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 3.74mL of buffer. 
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    5)Tube 5. Test 1.0 MIC (0.5µg/mL) 
    Add 303µL of Glucose Stock Solution 
    Add 0.50mL of Lactam Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 3.49mL of buffer. 
 
    6)Tube 6. Test 2.0 MIC (1.0µg/mL) 
    Add 303µL of Glucose Stock Solution 
    Add 1.0mL of Lactam Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 2.74mL of buffer. 
 
    7)Tube 7. Test 4.0 MIC (2.0µg/mL) 
    Add 303µL of Glucose Stock Solution 
    Add 2.0mL of Lactam Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 1.74mL of buffer. 
     
    8)Tube 8. Just Buffer. 
    Add 5mL of buffer 
 
    9)Tube 9. Glutathione 
    Add 303µL of Glucose Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 1mL of Glutathione Stock Solution 
    Add 2.74mL of buffer. 
 
    10)Tube 10. Erythromycin 
    Add 303µL of Glucose Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 1mL of Erythromycin Stock Solution 
    Add 2.74mL of buffer. 
 
11)Tube 11. DTT 
    Add 303µL of Glucose Stock Solution 
    Add 1mL of Bacteria Stock Solution 
    Add 1mL of DTT Stock Solution 
    Add 2.74mL of buffer. 
 
    12)Tube 12. Erythromycin Blank 
    Add 303µL of Glucose Stock Solution 
    Add 1mL of Doxycyclin Stock Solution 
    Add 3.74mL of buffer. 
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 Once these were prepared, all 12 tubes were incubated with shaking at 37oC for 
30 minutes. A standard curve was prepared as at the concentrations shown in table 7.1. 
Table 7.1 Standard Curve 
Well 
Plate  
  Final Concentrations  
  of Sugar  
Well (micromolar)  
1 0  
2 3  
3 6  
4 9  
5 12  
6 15  
7 18  
8 21  
9 24  
10 27  
11 30  
12 33  
 
Each tube was then precipitated via centrifugation and the supernatant was 
filtered with 0.2µm cellulose nitrate membrane. 50µL of each supernatant was pipetted 
into three wells each. The Amplex Red stock was prepared by dissolving the contents of 
the vial of Amplex Red reagent in 60 µL of DMSO. A Working Solution of fluorophore 
was prepared by mixing 1) 50µL of Amplex Red Stock, 2) 100µL of HRP, 3) 100µL of 
Glucose Oxidase, and 4) 4.75mL 1X Buffer. Then 50µL of this Working Solution was 
added to each well. The entire plate of wells was then incubated in a drawer for 30 
minutes. Fluorescence was then measured via a fluorometer. 
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7.2.5 Resin / Lysate Exposure 
1 liter of Staphylococcus aureus USF849 was cultured at 37oC for 24 hours. The 
culture was then centrifuged and washed. The resultant pellet was washed with PBS 
buffer and then resuspended in 5 ml of PBS buffer. The cells were then sonicated in an 
icebath for 30 minutes total, stopping every 5 minutes to check for overheating. The lysed 
cells were then centrifuged and the lysate extracted. The lysate was centrifuged again and 
the lystate extracted from the solids. Filtering the lysate yielded a slightly opaque yellow 
solution. 0.25226g of Lactam Thiolated Resin (12) was swelled in 0.5ml of DMSO and 
added the lysate solution. This mixture was then setup for 200 rpm shaking for 24 hours. 
Next, the lysate was filtered and repeatedly washed solid with boiling water and boiling 
ethanol. The solid was dried and 196mg of post lysate exposed resin material was 
collected which was a light brown mixture of amorphous and crystalline solid (looked 
like sand). After DIBAL cleavage, the solid was repeatedly freezed-dried with 100% 
deuterium oxide. Spectrum 8.49 was observed bearing stark similarity to Conezyme A. 
7.2.6 HPLC Experiments 
 All HPLC experiments (Spectra 8.51 through 8.59) were done using a Shimadzu 
LC-8A HPLC through a analytical reverse phase column to a Shimadzu SPD-10A UV-
VIS Detector at a 2ml/min flow rate. 10 µM solutions of standards: coenzyme A, N-
protio β-lactam, N-ethylthiolated β-lactam, N-sec-butylthiolated β-lactam, 
phenylthiolated β-lactam and the ethylthio-coenzyme A disulfide adduct were prepared. 
As well, mixtures of each thiolated β-lactam with coenzyme A were also produced. A cell 
lysate of S. aureus, prepared as above, was prepared and mixed with a equal volume of a 
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20 µM solution of N-thiolated β-lactam. Each mixture of coenzyme A and lactam 
provided two  new peaks, apparently the adduct and the resultant N-protio β-lactam. The 
mixture of lysate and lactam appeared to present the same adduct and N-protio β-lactam 
peaks. A reverse phase column was used with a eluent equal to 90% acetonitrile 10% 
water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER EIGHT 
SPECTRA 
 
Spectrum 8.01: 1H NMR (250 MHz, CDCl3) of imine 105: 
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 Spectrum 8.02: 1H NMR (250 MHz, CDCl3) of β-lactam 106: 
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 Spectrum 8.03: 1H NMR (250 MHz, CDCl3) of β-lactam 107: 
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 Spectrum 8.04: 1H NMR (250 MHz, CDCl3) of β-lactam 107b: 
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 Spectrum 8.05: 1H NMR (250 MHz, CDCl3) of phthalimide 111a: 
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 Spectrum 8.06: 1H NMR (250 MHz, CDCl3) of phthalimide 111b: 
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 Spectrum 8.07: 1H NMR (250 MHz, CDCl3) of phthalimide 111c: 
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 Spectrum 8.08: 1H NMR (250 MHz, CDCl3) of phthalimide 111d: 
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 Spectrum 8.09: 1H NMR (250 MHz, CDCl3) of phthalimide 111e: 
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 Spectrum 8.10: 1H NMR (250 MHz, CDCl3) of phthalimide 111f: 
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 Spectrum 8.11: 1H NMR (250 MHz, CDCl3) of phthalimide 111g: 
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 Spectrum 8.12: 1H NMR (250 MHz, CDCl3) of phthalimide 111h: 
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 Spectrum 8.13: 1H NMR (250 MHz, CDCl3) of phthalimide 111i: 
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 Spectrum 8.14: 1H NMR (250 MHz, CDCl3) of phthalimide 111j: 
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 Spectrum 8.15: 1H NMR (250 MHz, CDCl3) of phthalimide 111k: 
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 Spectrum 8.16: 1H NMR (250 MHz, CDCl3) of phthalimide 111l: 
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 Spectrum 8.17: 1H NMR (250 MHz, CDCl3) of phthalimide 111m: 
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 Spectrum 8.18: 1H NMR (250 MHz, CDCl3) of phthalimide 111n: 
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 Spectrum 8.19: 1H NMR (250 MHz, CDCl3) of phthalimide 111o: 
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 Spectrum 8.20: FTIR of phthalimide resin 164: 
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 Spectrum 8.21: 1H NMR (250 MHz, CDCl3) of lactam 109a: 
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 Spectrum 8.22: 1H NMR (250 MHz, CDCl3) of lactam 109b: 
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 Spectrum 8.23: 1H NMR (250 MHz, CDCl3) of lactam 109c: 
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 Spectrum 8.24: 1H NMR (250 MHz, CDCl3) of lactam 109d: 
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 Spectrum 8.25: 1H NMR (250 MHz, CDCl3) of lactam 109e: 
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 Spectrum 8.26: 1H NMR (250 MHz, CDCl3) of lactam 109f: 
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 Spectrum 8.27: 1H NMR (250 MHz, CDCl3) of lactam 109g: 
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 Spectrum 8.28: 1H NMR (250 MHz, CDCl3) of lactam 109h: 
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 Spectrum 8.29: 1H NMR (250 MHz, CDCl3) of lactam 109i: 
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 Spectrum 8.30: 1H NMR (250 MHz, CDCl3) of lactam 109j: 
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 Spectrum 8.31: 1H NMR (250 MHz, CDCl3) of lactam 109k: 
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 Spectrum 8.32: 1H NMR (250 MHz, CDCl3) of lactam 109l: 
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 Spectrum 8.33: 1H NMR (250 MHz, CDCl3) of lactam 109m1: 
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 Spectrum 8.34: 1H NMR (250 MHz, CDCl3) of lactam 109m: 
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 Spectrum 8.35: 1H NMR (250 MHz, CDCl3) of lactam 109n: 
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 Spectrum 8.36: 1H NMR (250 MHz, CDCl3) of (R)(+) lactam 152: 
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 Spectrum 8.37: 1H NMR (500 MHz, CDCl3) of (R)(-) lactam 153: 
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 Spectrum 8.38: 1H NMR (250 MHz, CDCl3) of (S)(+) lactam 154: 
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 Spectrum 8.39 1H NMR (250 MHz, CDCl3) of (S)(-) lactam 155: 
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 Spectrum 8.40: 1H NMR (250 MHz, CDCl3) of lactam 157b: 
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 Spectrum 8.41: 1H NMR (250 MHz, CDCl3) of lactam 157a: 
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 Spectrum 8.42: 1H NMR (250 MHz, CDCl3) of lactam 157c: 
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 Spectrum 8.43: 1H NMR (250 MHz, CDCl3) of lactam 158b: 
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 Spectrum 8.44: 1H NMR (250 MHz, CDCl3) of lactam 158a: 
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 Spectrum 8.45: 1H NMR (250 MHz, CDCl3) of lactam 160: 
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 Spectrum 8.46: FTIR of lactam resin 165: 
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 Spectrum 8.47: 1H NMR (250 MHz, CDCl3) of lactam 108OH: 
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 Spectrum 8.48: 1H NMR (250 MHz, CDCl3) of lactam p152: 
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 Spectrum 8.49: 1H NMR (250 MHz, CDCl3) of lactam 168: 
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 Spectrum 8.50: 1H NMR (250 MHz, CDCl3) of Coenzyme A Standard 9 and Resin-Lysate Extract 193: 
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 Spectrum 8.51: HPLC of Coenzyme A 9: 
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 Spectrum 8.52: HPLC N-Protio β-Lactam 107: 
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 Spectrum 8.53: HPLC of ethylthiolated β-lactam 109b: 
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 Spectrum 8.54: HPLC Purified Thioethyl Adduct: 
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 Spectrum 8.55: HPLC Immediately after mixture of Ethylthiolated β-Lactam and Coenzyme A: 
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 Spectrum 8.56: HPLC Immediately after mixture of sec-Butylthiolated β-Lactam and Coenzyme A: 
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 Spectrum 8.57: HPLC Immediately after mixture of Phenylthiolated β-Lactam and Coenzyme A: 
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 Spectrum 8.58: HPLC Immediately after mixture of ethylthiolated β-Lactam and S. aureus lysate: 
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 Spectrum 8.59: HPLC S. aureus lysate: 
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